RECOMBINANT TOXIN FRAGMENTS

Abstract: A polypeptide has first and second domains which enable the polypeptide to be translocated into a target cell or which increase the solubility of the polypeptide, or both, and further enable the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.

Description: RECOMBINANT TOXIN FRAGMENTS This invention relates to recombinant toxin fragments, to DNA encoding these fragments and to their uses such as in a vaccine and for in vitro and in vivo purposes The clostndial neurotoxins are potent inhibitors of calcium-dependent neurotransmitter secretion in neuronal cells. They are currently considered to mediate this activity through a specific endoproteolytic cleavage of at least one of three vesicle or pre-synaptic membrane associated proteins VAMP, syntaxin or SNAP-25 which are central to the vesicle docking and membrane fusion events of neurotransmitter secretion. The neuronal cell targeting of tetanus and botulinum neurotoxins is considered to be a receptor mediated event following which the toxins become internalised and subsequently traffic to the appropriate intracellular compartment where they effect their endopeptidase activity. The clostndial neurotoxins share a common architecture of a catalytic L-chain (LC, ca 50 kDa) disulphide linked to a receptor binding and translocating H-chain (HC, ca 1 00 kDa) . The HC polypeptide is considered to comprise all or part of two distinct functional domains. The carboxy-terminal half of the HC (ca 50 kDa), termed the H c domain, is involved in the high affinity, neurospecific binding of the neurotoxin to cell surface receptors on the target neuron, whilst the amino-termmal half, termed the H N domain (ca 50 kDa), is considered to mediate the translocation of at least some portion of the neurotoxin across cellular membranes such that the functional activity of the LC is expressed within the target cell. The H N domain also has the property, under conditions of low pH, of forming ion-permeabie channels in lipid membranes, this may in some manner relate to its translocation function. For botulinum neurotoxin type A (BoNT/A) these domains are considered to reside within ammo acid residues 872-1296 for the H c , ammo acid residues 449-871 for the H N and residues 1 -448 for the LC. Digestion with trypsin effectively degrades the H c domain of the BoNT/A to generate a non-toxic fragment designated LH N , which is no longer able to bind to and enter neurons (Fig . 1 ) . The LH N fragment so produced also has the property of enhanced solubility compared to both the parent holotoxin and the isolated LC. It is therefore possible to provide functional definitions of the domains within the neurotoxin molecule, as follows: (A) clostridial neurotoxin light chain: -a metalloprotease exhibiting high substrate specificity for vesicle and/or plasma - membrane associated proteins involved in the exocytotic process. In particular, it cleaves one or more of SNAP-25, VAMP (synaptobrevin / cellubrevin) and syntaxin. (B) clostridial neurotoxin heavy chain H N domain: -a portion of the heavy chain which enables translocation of that portion of the neurotoxin molecule such that a functional expression of light chain activity occurs within a target cell. -the domain responsible for translocation of the endopeptidase activity, following binding of neurotoxin to its specific cell surface receptor via the binding domain, into the target cell. -the domain responsible for formation of ion-permeable pores in lipid membranes under conditions of low pH. -the domain responsible for increasing the solubility of the entire polypeptide compared to the solubility of light chain alone. (C) clostridial neurotoxin heavy chain H c domain. -a portion of the heavy chain which is responsible for binding of the native holotoxin to cell surface receptor(s) involved in the intoxicating action of clostridial toxin prior to internaiisation of the toxin into the cell. The identity of the cellular recognition markers for these toxins is currently not understood and no specific receptor species have yet been identified although Kozaki et al. have reported that synaptotagmin may be the receptor for botulinum neurotoxin type B. It is probable that each of the neurotoxins has a different receptor. It is desirable to have positive controls for toxin assays, to develop clostridial toxin vaccines and to develop therapeutic agents incorporating desirable properties of clostridial toxin. However, due to its extreme toxicity, the handling of native toxin is hazardous. The present invention seeks to overcome or at least ameliorate problems associated with production and handling of clostridial toxin. Accordingly, the invention provides a polypeptide comprising first and second domains, wherein said first domain is adapted to cleave one or more vesicle or plasma-membrane associated proteins essential to neuronal exocytosis and wherein said second domain is adapted (i) to translocate the polypeptide into the cell or (ii) to increase the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both to translocate the polypeptide into the cell and to increase the solubility of the polypeptide compared to the solubility of the first domain on its own, said polypeptide being free of clostridial neurotoxin and free of any clostridial neurotoxin precursor that can be converted into toxin by proteolytic action. Accordingly, the invention may thus provide a single polypeptide chain containing a domain equivalent to a clostridial toxin light chain and a domain providing the functional aspects of the H N of a clostridial toxin heavy chain, whilst lacking the functional aspects of a clostridial toxin H c domain. For the purposes of the invention, the functional property or properties of the H of a clostridial toxin heavy chain that are required to be exhibited by the second domain of the polypeptide of the invention are either (i) translocation of the polypeptide into a cell, or (ii) increasing solubility of the polypeptide compared to solubility of the first domain on its own or (iii) both (i) and (ii) . References hereafter to a H N domain or to the functions of a H N domain are references to this property or properties. The second domain is not required to exhibit other properties of the H N domain of a clostridial toxin heavy chain. A polypeptide of the invention can thus be soluble but lack the translocation function of a native toxin-this is of use in providing an immunogen for vaccinating or assisting to vaccinate an individual against challenge by toxin In a specific embodiment of the invention described in an example below a polypeptide designated LH 423 /A elicited neutralising antibodies against type A neurotoxin. A polypeptide of the invention can likewise thus be relatively insoluble but retain the translocation function of a native toxin - this is of use if solubility is imparted to a composition made up of that polypeptide and one or more other components by one or more of said other components. The first domain of the polypeptide of the invention cleaves one or more vesicle or plasma-membrane associated proteins essential to the specific cellular process of exocytosis, and cleavage of these proteins results in inhibition of exocytosis, typically in a non-cytotoxic manner. The cell or cells affected are not restricted to a particular type or subgroup but can include both neuronal and non-neuronal cells. The activity of clostridial neurotoxins in inhibiting exocytosis has., indeed, been observed almost universally in eukaryotic cells expressing a relevant cell surface receptor, including such diverse cells as from Aplysia (sea slug), Drosophila (fruit fly) and mammalian nerve cells, and the activity of the first domain is to be understood as including a corresponding range of cells. The polypeptide of the invention may be obtained by expression of a recombinant nucleic acid, preferably a DNA, and is a single polypeptide, that is to say not cleaved into separate light and heavy chain domains. The polypeptide is thus available in convenient and large quantities using recombinant techniques. In a polypeptide according to the invention, said first domain preferably comprises a clostridial toxin light chain or a fragment or variant of a clostridial toxin light chain . The fragment is optionally an N-terminal, or C-terminal fragment of the light chain, or is an internal fragment, so long as it substantially retains the ability to cleave the vesicle or plasma-membrane associated protein essential to exocytosis. The minimal domains necessary for the activity of the light chain of clostridial toxins are described in J. Biol. Chem., Vol.267, No. 21 , July 1 992, pages 1 4721 - 14729. The variant has a different peptide sequence from the light chain or from the fragment, though it too is capable of cleaving the vesicle or plasma-membrane associated protein. It is conveniently obtained by insertion, deletion and/or substitution of a light chain or fragment thereof. In embodiments of the invention described below a variant sequence comprises (i) an N-terminal extension to a clostridial toxin light chain or fragment (ii) a clostridial toxin light chain or fragment modified by alteration of at least one amino acid (iii) a C-terminal extension to a clostridial toxin light chain or fragment, or (iv) combinations of 2 or more of (i)-(iii) . In further embodiments of the invention, the variant contains an amino acid sequence modified so that (a) there is no protease sensitive region between the LC and H N components of the polypeptide, or (b) the protease sensitive region is specific for a particular protease. This latter embodiment is of use if it is desired to activate the endopeptidase activity of the light chain in a particular environment oχ cell. Though, in general, the polypeptides of the invention are activated prior to administration. The first domain preferably exhibits endopeptidase activity specific for a substrate selected from one or more of SNAP-25, synaptobrevin/VAMP and syntaxin. The clostridial toxin is preferably botulinum toxin or tetanus toxin. In an embodiment of the invention described in an example below, the toxin light chain and the portion of the toxin heavy chain are of botulinum toxin type A. In a further embodiment of the invention described in an example below, the toxin light chain and the portion of the toxin heavy chain are of botulinum toxin type B. The polypeptide optionally comprises a light chain or fragment or variant of one toxin type and a heavy chain or fragment or variant of another toxin type. In a polypeptide according to the invention said second domain preferably comprises a clostridial toxin heavy chain H N portion or a fragment or variant of a clostridial toxin heavy chain H N portion . The fragment is optionally an N-terminal or C-terminal or internal fragment, so long as it retains the function of the H N domain Teachings of regions within the H N responsible for its function are provided for example in Biochemistry 1 995, 34, pages 1 51 75- 1 51 81 and Eur. J Biochem, 1 989, 1 85, pages 1 97-203. The variant has a different sequence from the H N domain or fragment, though it too retains the function of the H N domain It is conveniently obtained by insertion, deletion and/or substitution of a H N domain or fragment thereof. In embodiments of the invention, described below, it comprises (i) an N-terminal extension to a H N domain or fragment, (ii) a C-terminal extension to a H N domain or fragment, (iii) a modification to a H N domain or fragment by alteration of at least one ammo acid, or (iv) combinations of 2 or more of (i)-(iιi) . The clostridial toxin is preferably botulinum toxin or tetanus toxin. The invention also provides a polypeptide comprising a clostridial neurotoxin light chain and a N-terminal fragment of a clostridial neurotoxin heavy chain, the fragment preferably comprising at least 423 of the N-terminal ammo acids of the heavy chain of botulinum toxin type A, 41 7 of the N-terminal amino acids of the heavy chain of botulinum toxin type B or the equivalent number of N-terminal am o acids of the heavy chain of other types of clostridial toxin such that the fragment possesses an equivalent alignment of homologous ammo acid residues. These polypeptides of the invention are thus not composed of two or more polypeptides, linked for example by di-sulphide bridges into composite molecules. Instead, these polypeptides are single chains and are not active or their activity is significantly reduced in an in vitro assay of neurotoxin endopeptidase activity. Further, the polypeptides may be susceptible to be converted into a form exhibiting endopeptidase activity by the action of a proteolytic agent, such as trypsin In this way it is possible to control the endopeptidase activity of the toxin light chain. In a specific embodiment of the invention described in an example below, there is provided a polypeptide lacking a portion designated H c of a clostridial toxin heavy chain This portion, seen in the naturally produced toxin, is responsible for binding of toxin to cell surface receptors prior to interna sation of the toxin . This specific embodiment is therefore adapted so that it can not be converted into active toxin, for example by the action of a proteolytic enzyme The invention thus also provides a polypeptide comprising a clostndial toxin light chain and a fragment of a clostndial toxin heavy chain, said fragment being not capable of binding to those cell surface receptors involved in the intoxicating action of clostndial toxin, and it is preferred that such a polypeptide lacks an intact portion designated H c of a clostridial toxin heavy chain. In further embodiments of the invention there are provided compositions containing a polypeptide comprising a clostridial toxin light chain and a portion designated H N of a clostndial toxin heavy chain, and wherein the composition is free of clostndial toxin and free of any clostridial toxin precursor that may be converted into clostridial toxin by the action of a proteolytic enzyme. Examples of these compositions include those containing toxin light chain and H N sequences of botulinum toxin types A, B, C, , D, E, F and G. The polypeptides of the invention are conveniently adapted to bind to, or include, a ligand for targeting to desired cells. The polypeptide optionally comprises a sequence that binds to, for example, an immunoglobu n. A suitable sequence is a tandem repeat synthetic IgG binding domain derived from domain B of Staphylococcal protein A. Choice of immunoglobuhn specificity then determines the target for a polypeptide - immunoglobuhn complex. Alternatively, the - o - polypeptide comprises a non-clostridial sequence that binds to a cell surface receptor, suitable sequences including insulin-like growth factor-1 (IGF-1 ) which binds to its specific receptor on particular cell types and the 1 4 amino acid residue sequence from the carboxy-terminus of cholera toxin A subunit which is able to bind the cholera toxin B subunit and thence to GM 1 gangliosides. A polypeptide according to the invention thus, optionally, further comprises a third domain adapted for binding of the polypeptide to a cell. In a second aspect the invention provides a fusion protein comprising a fusion of (a) a polypeptide of the invention as described above with (b) a second polypeptide adapted for binding to a chromatography matrix so as to enable purification of the fusion protein using said chromatography matrix. It is convenient for the second polypeptide to be adapted to bind to an affinity matrix, such as a glutathione Sepharose, enabling rapid separation and purification of the fusion protein from an impure source, such as a cell extract or supernatant. One possible second purification polypeptide is glutathione-S-transferase (GST), and others will be apparent to a person of skill in the art, being chosen so as to enable purification on a chromatography column according to conventional techniques. As noted above, by proteolytic treatment, for example using trypsin, of a polypeptide of the invention it is possible to induce endopeptidase activity in the treated polypeptide. A third aspect of the invention provides a composition comprising a derivative of a clostridial toxin, said derivative retaining at least 10% of the endopeptidase activity of the clostridial toxin, said derivative further being non-toxic in vivo due to its inability to bind to cell surface receptors, and wherein the composition is free of any component, such as toxin or a further toxin derivative, that is toxic in vivo. The activity of the derivative preferably approaches that of natural toxin, and is thus preferably at least 30% and most preferably at least 60% of natural toxin. The overall endopeptidase activity of the composition will, of course, also be determined by the amount of the derivative that is present. While it is known to treat naturally produced clostridial toxin to remove the H domain, this treatment does not totally remove toxicity of the preparation, instead some residual toxin activity remains. Natural toxin treated in this way is therefore still not entirely safe. The composition of the invention, derived by treatment of a pure source of polypeptide advantageously is free of toxicity, and can conveniently be used as a positive control in a toxin assay, as a vaccine against clostridial toxin or for other purposes where it is essential that there is no residual toxicity in the composition. The invention enables production of the polypeptides and fusion proteins of the invention by recombinant means. A fourth aspect of the invention provides a nucleic acid encoding a polypeptide or a fusion protein according to any of the aspects of the invention described above. In one embodiment of this aspect of the invention, a DNA sequence provided to code for the polypeptide or fusion protein is not derived from native clostridial sequences, but is an artificially derived sequence not preexisting in nature. A specific DNA (SEQ ID NO: 1 ) described in more detail below encodes a polypeptide or a fusion protein comprising nucleotides encoding residues 1 -871 of a botulinum toxin type A. Said polypeptide comprises the light chain domain and the first 423 amino acid residues of the amino terminal portion of a botulinum toxin type A heavy chain. This recombinant product is designated LH 423 /A (SEQ ID NO: 2) . In a second embodiment of this aspect of the invention a DNA sequence which codes for the polypeptide or fusion protein is derived from native clostridial sequences but codes for a polypeptide or fusion protein not found in nature. A specific DNA (SEQ ID NO: 1 9) described in more detail below encodes a polypeptide or a fusion protein and comprises nucleotides encoding residues 1 - 1 1 71 of a botulinum toxin type B. Said polypeptide comprises the light chain domain and the first 728 am o acid residues of the ammo terminal protein of a botulinum type B heavy chain. This recombinant product is designated LH 728 /B (SEQ ID NO: 20) . The invention thus also provides a method of manufacture of a polypeptide comprising expressing in a host cell a DNA according to the third aspect of the invention. The host cell is suitably not able to cleave a polypeptide or fusion protein of the invention so as to separate light and heavy toxin chains; for example, a non-clostridial host. The invention further provides a method of manufacture of a polypeptide comprising expressing in a host cell a DNA encoding a fusion protein as described above, purifying the fusion protein by elution through a chromatography column adapted to retain the fusion protein, eluting through said chromatography column a ligand adapted to displace the fusion protein and recovering the fusion protein. Production of substantially pure fusion protein is thus made possible. Likewise, the fusion protein is readily cleaved to yield a polypeptide of the invention, again in substantially pure form, as the second polypeptide may conveniently be removed using the same type of chromatography column. The LH N /A derived from dichain native toxin requires extended digestion with trypsin to remove the C-terminal 1 /2 of the heavy chain, the H c domain. The loss of this domain effectively renders the toxin inactive in vivo by preventing its interaction with host target cells. There is, however, a residual toxic activity which may indicate a contaminating, trypsin insensitive, form of the whole type A neurotoxin. In contrast, the recombinant preparations of the invention are the product of a discreet, defined gene coding sequence and can not be contaminated by full length toxin protein. Furthermore, the product as recovered from E. coli, and from other recombinant expression hosts, is an inactive single chain peptide or if expression hosts produce a processed, active polypeptide it is not a toxin. Endopeptidase activity of LH 423 /A, as assessed by the current in vitro peptide cleavage assay, is wholly dependent on activation of the recombinant molecule between residues 430 and 454 by trypsin. Other proteolytic enzymes that cleave between these two residues are generally also suitable for activation of the recombinant molecule Trypsin cleaves the peptide bond C-terminal to Argmine or C-terminal to Lysme and is suitable as these residues are found in the 430-454 region and are exposed (see The recombinant polypeptides of the invention are potential therapeutic agents for targeting to cells expressing the relevant substrate but which are not implicated in effecting botulism. An example might be where secretion of neurotransmitter is inappropriate or undesirable or alternatively where a neuronal cell is hyperactive in terms of regulated secretion of substances other than neurotransmitter. In such an example the function of the H c domain of the native toxin could be replaced by an alternative targeting sequence providing, for example, a cell receptor hgand and/or translocation domain. One application of the recombinant polypeptides of the invention will be as a reagent component for synthesis of therapeutic molecules, such as disclosed in WO-A-94/21 300. The recombinant product will also find application as a non-toxic standard for the assessment and development of in vitro assays for detection of functional botulinum or tetanus neurotoxins either in foodstuffs or in environmental samples, for example as disclosed in EP-A-07631 31 . A further option is addition, to the C-terminal end of a polypeptide of the invention, of a peptide sequence which allows specific chemical conjugation to targeting gands of both protein and non-protein origin. In yet a further embodiment an alternative targeting hgand is added to the N- terminus of polypeptides of the invention. Recombinant LH N derivatives have been designated that have specific protease cleavage sites engineered at the C-termmus of the LC at the putative trypsin sensitive region and also at the extreme C- terminus of the complete protein product. These sites will enhance the activational specificity of the recombinant product such that the dichain species can only be activated by proteolytic cleavage of a more predictable nature than use of trypsin. The LH N enzymatically produced from native BoNT/A is an efficient immunogen and thus the recombinant form with its total divorce from any full length neurotoxin represents a vaccine component. The recombinant product may serve as a basal reagent for creating defined protein modifications in support of any of the above areas. Recombinant constructs are assigned distinguishing names on the basis of their amino acid sequence length and their Light Chain (L-chain, L) and Heavy Chain (H- chain, H) content as these relate to translated DNA sequences in the public domain or specifically to SEQ ID NO: 2 and SEQ ID NO: 20. The ' LH' designation is followed by 7X ' where 'X' denotes the corresponding clostridial toxin serotype or class, e.g . 'A' for botulinum neurotoxin type A or 'TeTx' for tetanus toxin. Sequence variants from that of the native toxin polypeptide are given in parenthesis in standard format, namely the residue position number prefixed by the residue of the native sequence and suffixed by the residue of the variant. Subscript number prefixes indicate an amino-terminal (N-terminal) extension, or where negative a deletion, to the translated sequence. Similarly, subscript number suffixes indicate a carboxy terminal (C-terminal) extension or where negative numbers are used, a deletion. Specific sequence inserts such as protease cleavage sites are indicated using abbreviations, e.g. Factor Xa is abbreviated to FXa. L- chain C-terminal suffixes and H-chain N-terminal prefixes are separated by a 7 to indicate the predicted junction between the L and H-chains. Abbreviations for engineered ligand sequences are prefixed or suffixed to the clostridial L-chain or H- chain corresponding to their position in the translation product. Following this nomenclature, LH Λ 4 2„3/'A SEQ ID NO: 2, containing the entire L-chain and 423 ammo acids of the H-chain of botulinum neurotoxin type A; ,LH Λ 2„3/'A a variant of this molecule, containing a two ammo acid extension to the N-terminus of the L-chain, - /2 H 23 /A a further variant in which the molecule contains a two ammo acid extension on the N-termmus of both the L- chain and the H-chain; 2L-FXa 2H 2 3 A a further variant containing a two amino acid extension to the N-terminus of the L-chain, and a Factor Xa cleavage sequence at the C-terminus of the L-chain which, after cleavage of the molecule with Factor Xa leaves a two ammo acid N-terminal extension to the H- chain component; and 2 L FXa/2 H 423 /A-IGF- 1 = a variant of this molecule which has a further C-terminal extension to the H-chain, in this example the insulin-like growth factor 1 (IGF-1 ) sequence. There now follows description of specific embodiments of the invention, illustrated by drawings in which: Fig. 1 shows a schematic representation of the domain structure of botulinum neurotoxin type A (BoNT/A); Fig. 2 shows a schematic representation of assembly of the gene for an embodiment of the invention designated LH 423 /A; Fig. 3 is a graph comparing activity of native toxin, trypsin generated "native" LH N /A and an embodiment of the invention designated 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) in an in vitro peptide cleavage assay; Fig. 4 is a comparison of the first 33 amino acids in published sequences of native toxin and embodiments of the invention; Fig. 5 shows the transition region of an embodiment of the invention designated L/ 4 H 423 /A illustrating insertion of four amino acids at the N-terminus of the H N sequence; amino acids coded for by the Eco 47 III restriction endonuclease cleavage site are marked and the H N sequence then begins ALN...; Fig . 6 shows the transition region of an embodiment of the invention designated L FXa/3 H 423 /A illustrating insertion of a Factor Xa cleavage site at the C-terminus of the L-chain, and three additional amino acids coded for at the N-terminus of the H- sequence; the N-terminal amino acid of the cleavage-activated H N will be cysteine; Fig. 7 shows the C-terminal portion of the amino acid sequence of an embodiment of the invention designated L FXa/3 H 423 /A-IGF-1 , a fusion protein; the IGF-1 sequence begins at position G 882 ; Fig. 8 shows the C-terminal portion of the amino acid sequence of an embodiment of the invention designated L FXa/3 H 423 /A-CtxA14, a fusion protein; the C-terminal CtxA sequence begins at position Q 882 ; Fig.9 shows the C-termiπal portion of the amino acid sequence ofan embodiment of the invention designated L FXa/3 H 423 /A-ZZ, a fusion protein; the C-terminal ZZ sequence begins at position A 890 immediately after a genenase recognition site (underlined); show schematic representations of manipulations of Figs. 1 0 & 1 1 polypeptides of the invention; Fig. 1 0 shows LH 423 /A with N-terminal addition of an affinity purification peptide (in this case GST) and C-terminal addition of an Ig binding domain; protease cleavage sites R1 , R2 and R3 enable selective enzymatic separation of domains; Fig. 1 1 shows specific examples of protease cleavage sites R1 , R2 and R3 and a C-terminal fusion peptide sequence; Fig. 12 shows the trypsin sensitive activation region of a polypeptide of the invention; Fig. 13 shows Western blot analysis of recombinant LH 107 /B expressed from E.coli; panel A was probed with anti- BoNT/B antiserum; Lane 1 , molecular weight standards; lanes 2 & 3, native BoNT/B; lane 4, immunopurified LH 107 /B; panel B was probed with anti-T7 peptide tag antiserum; lane 1 , molecular weight standards; lanes 2 & 3, positive control E.coli T7 expression; lane 4 immunopurified LH 107 /B. The sequence listing that accompanies this application contains the following sequences:- SEQ ID NO: Sequence 1 DNA coding for LH 423 /A 2 LH 423 /A 3 DNA coding for 23 LH 423 /A (Q 2 E,N 26 K,A 27 Y) , of which an N-terminal portion is shown in Fig. 4. 4 23 LH 423 /A (Q 2 E,N 26 K,A 27 Y) 5 DNA coding for 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) , of which an N- terminal portion is shown in Fig .4 6 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) 7 DNA coding for native BoNT/A according to Binz et al 8 native BoNT/A according to Binz et al 9 DNA coding for L /4 H 423 /A 10 L /4 H 423 /A 1 1 DNA coding for L FXa / 3 H 423 /A 1 2 L FXa / 3 H 423 /A 1 3 DNA coding for L FXa / 3 H 423 /A-IGF-1 1 4 FXa / 3 H 423 /A-IGF-1 1 5 DNA coding for L FXa / 3 H 423 /A-CtxA14 1 6 L FXa / 3 H 423 /A-CtxA14 1 7 DNA coding for L FXa/3 H 423 /A-ZZ 1 8 L FXa/3 H 423 /A-ZZ 1 9 DNA coding for LH 728 /B 20 LH 728 /B 21 DNA coding for LH 417 /B 22 LH 417 /B 23 DNA coding for LH 107 /B 24 LH 107 /B 25 DNA coding for LH 423 /A (Q 2 E,N 26 K,A 27 Y) 26 LH 423 /A (Q 2 E,N 26 K,A 27 Y) 27 DNA coding for LH 417 /B wherein the first 274 bases are modified to have an E. coli codon bias 28 DNA coding for LH 417 /B wherein bases 691 - 1 641 of the native BoNT/B sequence have been replaced by a degenerate DNA coding for amino acid residues 231 -547 of the native BoNT/B polypeptide Example 1 A 261 6 base pair, double stranded gene sequence (SEQ ID NO: 1 ) has been assembled from a combination of synthetic , chromosomal and polymerase-chain-reaction generated DNA (Figure 2) . The gene codes for a polypeptide of 871 amino acid residues corresponding to the entire light-chain (LC, 448 amino acids) and 423 residues of the amino terminus of the heavy-chain (H c ) of botulinum neurotoxin type A. This recombinant product is designated the LH 423 /A fragment (SEQ ID NO: 2). Construction of the recombinant product The first 91 8 base pairs of the recombinant gene were synthesised by concatenation of short oligonucleotides to generate a coding sequence with an E. coli codon bias. Both DNA strands in this region were completely synthesised as short overlapping oligonucleotides which were phosphorylated, annealed and ligated to generate the full synthetic region ending with a unique Kpn\ restriction site. The remainder of the LH 423 /A coding sequence was PCR amplified from total chromosomal DNA from Clostridium botulinum and annealed to the synthetic portion of the gene. The internal PCR amplified product sequences were then deleted and replaced with the native, fully sequenced, regions from clones of C. botulinum chromosomal origin to generate the final gene construct. The final composition is synthetic DNA (bases 1 -913), polymerase amplified DNA (bases 914-1 1 38 and 1 976-261 6) and the remainder is of C. botulinum chromosomal origin (bases 1 1 39- 1 975) . The assembled gene was then fully sequenced and cloned into a variety of E. coli plasmid vectors for expression analysis. Expression of the recombinant gene and recovery of protein product The DNA is expressed in E. coli as a single nucleic acid transcript producing a soluble single chain polypeptide of 99,951 Daltons predicted molecular weight. The gene is currently expressed in E. coli as a fusion to the commercially available coding sequence of glutathione S-transferase (GST) of Schistosoma japonicum but any of an extensive range of recombinant gene expression vectors such as pEZZ1 8, pTrc99, pFLAG or the pMAL series may be equally effective as might expression in other prokaryotic or eukaryotic hosts such as the Gram positive bacilli, the yeast P. pastoris or in insect or mammalian ceils under appropriate conditions. Currently, E. coli harbouring the expression construct is grown in Luria-Bertani broth (L-broth pH 7.0, containing 10 g/l bacto-tryptone, 5 g/l bacto-yeast extract and 10 g/l sodium chloride) at 37 ° C until the cell density (biomass) has an optical absorbance of 0.4- 0.6 at 600 nm and the cells are in mid-logarithmic growth phase. Expression of the gene is then induced by addition of isopropylthio- ?-D-galactosidase (IPTG) to a final concentration of 0.5 mM. Recombinant gene expression is allowed to proceed for 90 min at a reduced temperature of 25°C. The cells are then harvested by centrifugation, are resuspended in a buffer solution containing 10 mM Na 2 HP0 4 , 0.5 M NaCI, 10 mM EGTA, 0.25% Tween, pH 7.0 and then frozen at -20°C. For extraction of the recombinant protein the cells arβ-disrupted by sonication. The cell extract is then cleared of debris by centrifugation and the cleared supernatant fluid containing soluble recombinant fusion protein (GST- LH 423 /A) is stored at -20°C pending purification. A proportion of recombinant material is not released by the sonication procedure and this probably reflects insolubility or inclusion body formation. Currently we do not extract this material for analysis but if desired this could be readily achieved using methods known to those skilled in the art. The recombinant GST- LH 423 /A is purified by adsorption onto a commercially prepared affinity matrix of glutathione Sepharose and subsequent elution with reduced glutathione. The GST affinity purification marker is then removed by proteolytic cleavage and reabsorption to glutathione Sepharose; recombinant LH 423 /A is recovered in the non-adsorbed material. Construct variants A variant of the molecule, LH 423 /A (Q 2 E,N 26 K,A 27 Y) (SEQ ID NO: 26) has been produced in which three amino acid residues have been modified within the light chain of LH 423 /A producing a polypeptide containing a light chain sequence different to that of the published amino acid sequence of the light chain of BoNT/A . Two further variants of the gene sequence that have been expressed and the corresponding products purified are 23 LH 423 /A (Q 2 E,N 26 K,A 27 Y) (SEQ ID NO: 4) which has a 23 amino acid N-terminal extension as compared to the predicted native L-chain of BoNT/A and 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) (SEQ ID NO: 6) which has a 2 amino acid N-terminal extension (Figure 4) . In yet another variant a gene has been produced which contains a Eco 47 III restriction site between nucleotides 1 344 and 1 345 of the gene sequence given in (SEQ ID NO: 1 ) . This modification provides a restriction site at the position in the gene representing the interface of the heavy and light chains in native neurotoxin, and provides the capability to make insertions at this point using standard restriction enzyme methodologies known to those skilled in the art. It will also be obvious to those skilled in the art that any one of a number of restriction sites could be so employed, and that the fco 47 III insertion simply exemplifies this approach. Similarly, it would be obvious for one skilled in the art that insertion of a restriction site in the manner described could be performed on any gene of the invention. The gene described, when expressed, codes for a polypeptide, L /4 H 423 /A (SEQ ID NO: 10), which contains an additional four amino acids between amino acids 448 and 449 of LH 423 /A at a position equivalent to the amino terminus of the heavy chain of native BoNT/A. A variant of the gene has been expressed, L FXa/3 H 423 /A (SEQ ID NO- 12), in which a specific proteolytic cleavage site was incorporated at the carboxy-terminal end of the light chain domain, specifically after residue 448 of L /4 H 423 /A. The cleavage site incorporated was for Factor Xa protease and was coded for by modification of SEQ ID NO: 1 . It will be apparent to one skilled in the art that a cleavage site for another specified protease could be similarly incorporated, and that any gene sequence coding for the required cleavage site could be employed . Modification of the gene sequence in this manner to code for a defined protease site could be performed on any gene of the invention. Variants of L FXa/3 H 423 /A have been constructed in which a third domain is present at the carboxy-terminal end of the polypeptide which incorporates a specific binding activity into the polypeptide. Specific examples described are: 0 ) L Fχ a 3 2 3 /A - | G F - 1 < SEQ I D N 0 : 1 4 > < ,n which the carboxy-terminal domain has a sequence equivalent to that of insulin-like growth factor-1 (IGF-1 ) and is able to bind to the insulin-like growth factor receptor with high affinity; (2) L FXa/3 H 423 /A-CtxA1 4 (SEQ ID NO: 1 6) , in which the carboxy-terminal domain has a sequence equivalent to that of the 14 amino acids from the carboxy-terminus of the A-subunit of cholera toxin (CtxA) and is thereby able to interact with the cholera toxin B-subunit pentamer; and (3) L FXa/3 H 423 /A-ZZ (SEQ ID NO: 1 8) , in which the carboxy-terminal domain is a tandem repeating synthetic IgG binding domain. This variant also exemplifies another modification applicable to the current invention, namely the inclusion in the gene of a sequence coding for a protease cleavage site located between the end of the clostridial heavy chain sequence and the sequence coding for the binding gand. Specifically in this example a sequence is inserted at nucleotides 2650 to 2666 coding for a genenase cleavage site. Expression of this gene produces a polypeptide which has the desired protease sensitivity at the interface between the domain providing H N function and the binding domain. Such a modification enables selective removal of the C-terminal binding domain by treatment of the polypeptide with the relevant protease. It will be apparent that any one of a number of such binding domains could be incorporated into the polypeptide sequences of this invention and that the above examples are merely to exemplify the concept. Similarly, such binding domains can be incorporated into any of the polypeptide sequences that are the basis of this invention. Further, it should be noted that such binding domains could be incorporated at any appropriate location within the polypeptide molecules of the invention. Further embodiments of the invention are thus illustrated by a DNA of the invention further comprising a desired restriction endonuclease site at a desired location and by a polypeptide of the invention further comprising a desired protease cleavage site at a desired location. The restriction endonuclease site may be introduced so as to facilitate further manipulation of the DNA in manufacture of an expression vector for expressing a polypeptide of the invention; it may be introduced as a consequence of a previous step in manufacture of the DNA; it may be introduced by way of modification by insertion, substitution or deletion of a known sequence. The consequence of modification of the DNA may be that the amino acid sequence is unchanged, or may be that the amino acid sequence is changed, for example resulting in introduction of a desired protease cleavage site, either way the polypeptide retains its first and second domains having the properties required by the invention. Figure 10 is a diagrammatic representation of an expression product exemplifying features described in this example. Specifically, it illustrates a single polypeptide incorporating a domain equivalent to the light chain of botulinum neurotoxin type A and a domain equivalent to the H N domain of the heavy chain of botulinum neurotoxin type A with a N-terminal extension providing an affinity purification domain, namely GST, and a C-terminal extension providing a ligand binding domain, namely an IgG binding domain. The domains of the polypeptide are spatially separated by specific protease cleavage sites enabling selective enzymatic separation of domains as exemplified in the Figure. This concept is more specifically depicted in Figure 1 1 where the various protease sensitivities are defined for the purpose of example. Assay of product activity The LC of botulinum neurotoxin type A exerts a zinc-dependent endopeptidase activity on the synaptic vesicle associated protein SNAP-25 which it cleaves in a specific manner at a single peptide bond. The 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) (SEQ ID NO: 6) cleaves a synthetic SNAP-25 substrate in vitro under the same conditions as the native toxin (Figure 3) . Thus, the modification of the polypeptide sequence of 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) relative to the native sequence and within the minimal functional LC domains does not prevent the functional activity of the LC domains. This activity is dependent on proteolytic modification of the recombinant GST- 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) to convert the single chain polypeptide product to a disulphide linked dichain species. This is currently done using the proteolytic enzyme trypsin. The recombinant product ( 100-600 μg/ml) is incubated at 37 °C for 10-50 minutes with trypsin ( 10 μg/ml) in a solution containing 140 mM NaCI, 2.7 mM KCI, 10 mM Na 2 HP0 4 , 1 .8 mM KH 2 P0 4 , pH 7.3. The reaction is terminated by addition of a 100-fold molar excess of trypsin inhibitor. The activation by trypsin generates a disulphide linked dichain species as determined by polyacrylamide gel electrophoresis and immunoblotting analysis using polyclonal anti-botulinum neurotoxin type A antiserum. 2 LH 423 /A is more stable in the presence of trypsin and more active in the in vitro peptide cleavage assay than is 23 LH 423 /A. Both variants, however, are fully functional in the in vitro peptide cleavage assay. This demonstrates that the recombinant molecule will tolerate N-terminal amino acid extensions and this may be expanded to other chemical or organic moieties as would be obvious to those skilled in the art. Example 2 As a further exemplification of this invention a number of gene sequences have been assembled coding for polypeptides corresponding to the entire light-chain and varying numbers of residues from the amino terminal end of the heavy chain of botulinum neurotoxin type B. In this exemplification of the disclosure the gene sequences assembled were obtained from a combination of chromosomal and polymerase-chain-reaction generated DNA, and therefore have the nucleotide sequence of the equivalent regions of the natural genes, thus exemplifying the principle that the substance of this disclosure can be based upon natural as well as a synthetic gene sequences. The gene sequences relating to this example were all assembled and expressed using methodologies as detailed in Sambrook J, Fritsch E F & Maniatis T ( 1 989) Molecular Cloning: A Laboratory Manual (2nd Edition), Ford N, Nolan C, Ferguson M & Ockler M (eds), Cold Spring Harbor Laboratory Press, New York, and known to those skilled in the art. A- gene has been assembled coding for a polypeptide of 1 171 amino acids corresponding to the entire light-chain (443 amino acids) and 728 residues from the amino terminus of the heavy chain of neurotoxin type B. Expression of this gene produces a polypeptide, LH 728 /B (SEQ ID NO: 20), which lacks the specific neuronal binding activity of full length BoNT/B. A gene has also been assembled coding for a variant polypeptide, LH 417 /B (SEQ ID NO: 22), which possesses an amino acid sequence at its carboxy terminus equivalent by ammo acid homology to that at the carboxy-terminus of the heavy chain fragment in native LH N /A . A gene has also been assembled coding for a variant polypeptide, LH, 07 /B (SEQ ID NO: 24) , which expresses at its carboxy-terminus a short sequence from the ammo terminus of the heavy chain of BoNT/B sufficient to maintain solubility of the expressed polypeptide. Construct Variants A variant of the coding sequence for the first 274 bases of the gene shown in SEQ ID NO. 21 has been produced which whilst being a non-native nucleotide sequence still codes for the native polypeptide. Two double stranded, a 268 base pair and a 951 base pair, gene sequences have been created using an overlapping primer PCR strategy. The nucleotide bias of these sequences was designed to have an E. coli codon usage bias. For the first sequence, six oligonucleotides representing the first (5') 268 nucleotides of the native sequence for botulinum toxin type B were synthesised. For the second sequence 23 oligonucleotides representing internal sequence nucleotides 691 -1641 of the native sequence for botulinum toxin type B were synthesised. The oligonucleotides ranged from 57-73 nucleotides in length. Overlapping regions, 1 7-20 nucleotides, were designed to give melting temperatures in the range 52-56°C. In addition, terminal restriction endonuclease sites of the synthetic products were constructed to facilitate insertion of these products into the exact corresponding region of the native sequence. The 268 bp 5' synthetic sequence has been incorporated into the gene shown in SEQ ID NO: 21 in place of the original first 268 bases (and is shown in SEQ ID NO: 27) . Similarly the sequence could be inserted into other genes of the examples. Another variant sequence equivalent to nucleotides 691 to 1 641 of SEQ ID NO: 21 , and employing non-native codon usage whilst coding for a native polypeptide sequence, has been constructed using the internal synthetic sequence. This sequence (SEQ ID NO: 28) can be incorporated, alone or in combination with other variant sequences, in place of the equivalent coding sequence in any of the genes of the example. Example 3 An exemplification of the utility of this invention is as a non-toxic and effective immunogen. The non-toxic nature of the recombinant, single chain material was demonstrated by intraperitoneal administration in mice of GST- 2 LH 423 /A. The polypeptide was prepared and purified as described above. The amount of immunoreactive material in the final preparation was determined by enzyme linked immunosorbent assay (ELISA) using a monoclonal antibody (BA1 1 ) reactive against a conformation dependent epitope on the native LH N /A. The recombinant material was serially diluted in phosphate buffered saline (PBS; NaCI 8 g/l, KCI 0.2 g/l, Na 2 HP0 4 1 . 1 5 g/l, KH 2 P0 4 0.2 g/l, pH 7.4) and 0.5 ml volumes injected into 3 groups of 4 mice such that each group of mice received 1 0, 5 and 1 micrograms of material respectively. Mice were observed for 4 days and no deaths were seen. For immunisation, 20 μg of GST- 2 LH 423 /A in a 1 .0 ml volume of water-in-oil emulsion ( 1 : 1 vohvol) using Freund's complete (primary injections only) or Freund's incomplete adjuvant was administered into guinea pigs via two sub-cutaneous dorsal injections. Three injections at 10 day intervals were given (day 1 , day 10 and day 20) and antiserum collected on day 30. The antisera were shown by ELISA to be immunoreactive against native botulinum neurotoxin type A and to its derivative LH N /A. Antisera which were botulinum neurotoxin reactive at a dilution of 1 :2000 were used for evaluation of neutralising efficacy in mice. For neutralisation assays 0.1 ml of antiserum was diluted into 2.5 ml of gelatine phosphate buffer (GPB; Na 2 HP0 4 anhydrous 10 g/l, gelatin (Difco) 2 g/l, pH 6.5- 6.6) containing a dilution range from 0.5 μg (5X10 6 g) to 5 picograms (5X 10 12 g) . Aliquots of 0.5 ml were injected into mice intraperitoneally and deaths recorded over a 4 day period. The results are shown in Table 1 and Table 2. It can clearly be seen that 0.5 ml of 1 :40 diluted anti- GST- 2 LH 423 /A antiserum can protect mice against intraperitoneal challenge with botulinum neurotoxin in the range 5 pg - 50 ng ( 1 - 1 0,000 mouse LD50; 1 mouse LD50 = 5 pg) . TABLE 1 . Neutralisation of botulinum neurotoxin in mice by guinea pig anti-GST- 2 LH 423 /A antiserum. Botulinum Toxin/mouse Survivors 0.5μg O.CO5μg 0.0005/ g 0.5ng O.OOδng 5pg Control On Day (no toxin) 1 4 4 4 4 4 4 2 4 4 4 4 4 4 3 4 4 4 4 4 4 4 4 4 4 4 4 4 TABLE 2. Neutralisation of botulinum neurotoxin in mice by non-immune guinea pig antiserum. Botulinum Toxin/mouse Survivors 0.5/ g O.OOδμg O.OOOδμg O.δng O.OOδng 5pg Control On Day (no toxin) 1 2 4 2 0 4 3 4 4 4 Example 4 Expression of recombinant LH 107 /B in E. coli. As an exemplification of the expression of a nucleic acid coding for a LH N of a clostridial neurotoxin of a serotype other than botulinum neurotoxin type A, the nucleic acid sequence (SEQ ID NO: 23) coding for the polypeptide LH 107 /B (SEQ ID NO: 24) was inserted into the commercially available plasmid pET28a (Novogen, Madison, Wl, USA) . The nucleic acid was expressed in E. coli BL21 (DE3) (New England BioLabs, Beverley, MA, USA) as a fusion protein with a N-terminal T7 fusion peptide, under IPTG induction at 1 mM for 90 minutes at 37 °C. Cultures were harvested and recombinant protein extracted as described previously for LH 423 /A. Recombinant protein was recovered and purified from bacterial paste lysates by immunoaffinity adsorption to an immobilised anti-T7 peptide monoclonal antibody using a T7 tag purification kit (New England bioLabs, Beverley, MA, USA) . Purified recombinant protein was analysed by gradient (4-20%) denaturing SDS- polyacrylamide gel electrophoresis (Novex, San Diego, CA, USA) and western blotting using poiyclonal anti-botulinum neurotoxin type antiserum or anti-T7 antiserum. Western blotting reagents were from Novex, immunostained proteins were visualised using the Enhanced Chemi-Luminescence system (ECL) from Amersham. The expression of an anti-T7 antibody and anti-botulinum neurotoxin type B antiserum reactive recombinant product is demonstrated in Figure 1 3. The recombinant product was soluble and retained that part of the light chain responsible for endopeptidase activity. The invention thus provides recombinant polypeptides useful inter alia as immunogens, enzyme standards and components for synthesis of molecules as described in WO-A-94/21 300. SEQUENCE LISTING (1) GENERAL INFORMATION. (l) APPLICANT: (A) NAME: MICROBIOLOGICAL RESEARCH AUTHORITY (B) STREET: Centre For Applied Microbiology And Research, Porton Down (C) CITY: Salisbury (D) STATE: Wiltshire (E) COUNTRY. UK (F) POSTAL CODE (ZIP) . SP4 OJG (A) NAME ■ THE SPEYWOOD LABORATORY LIMITED (B) STREET- 14 Kensington Square (C) CITY: London (E) COUNTRY. UK (F) POSTAL CODE (ZIP) ■ W8 5HH (A) NAME- FOSTER; Keith Alan (B) STREET- Centre For Applied Microbiology And Research, Porton Down (C) CITY: Salisbury (D) STATE: Wiltshire (E) COUNTRY: UK (F) POSTAL CODE (ZIP) . SP4 OJG (A) NAME: QUINN; Conrad Padraig (B) STREET: Centre For Applied Microbiology And Research, Porton Down (C) CITY: Salisbury (D) STATE: Wiltshire (E) COUNTRY: UK (F) POSTAL CODE (ZIP) : SP4 OJG (A) NAME. SHONE; Clifford Charles (B) STREET: Centre For Applied Microbiology And Research, Porton Down (C) CITY: Salisbury (D) STATE: Wiltshire (E). COUNTRY: UK (F) POSTAL CODE (ZIP) : SP4 OJG (ii) TITLE OF INVENTION: Recombinant Toxin Fragments (iii) NUMBER OF SEQUENCES: 28 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPU ER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO) (2) INFORMATION FOR SEQ ID NO: 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2616 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) ( IX ) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..2616 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1: ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp lie Ala Tyr lie Lys lie Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144 Val Lys Ala Phe Lys lie His Asn Lys lie Trp Val lie Pro Glu Arg 35 40 45 GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 336 Arg lie Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser lie Val 100 105 110 CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 384 Arg Gly lie Pro Phe Trp Gly Gly Ser Thr lie Asp Thr Glu Leu Lys 115 120 125 GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val lie Asp Thr Asn Cys lie Asn Val lie Gin Pro Asp Gly Ser Tyr 130 135 140 AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val lie lie Gly Pro Ser Ala Asp lie 145 150 155 160 ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 lie Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr lie Arg Phe Ser Pro Asp Phe 180 185 190 ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu lie His Ala Gly His Arg Leu Tyr Gly lie Ala lie Asn Pro Asn 225 230 235 240 CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 7GR Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG aifi Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 91? Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 3 00 GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lvs 305 310 315 3 ^ 0 TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 33 5 AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 3 65 TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tvr 370 375 380 ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arα 420 425 430 GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lvs 435 440 445 * GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG TTT TTT 1392 Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460 AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA GAA GAA 1440 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480 ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT AGT TTA 1488 He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 495 GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT GAA CCT 1536 Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510 GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC CAA TTA 1584 Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525 GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG TAT GAG 1632 Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540 TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA TTT GAA 1680 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560 CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA GCA TTA 1728 His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575 TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT GTA AAG 1776 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590 AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG GTA GAA 1824 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605 CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT ACT ACG 1872 Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620 GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA CCT GCT 1920 Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly Pro Ala 625 630 635 640 TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT GCT TTA 1968 Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655 ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG ATT GCA 2016 He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670 ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG AAT AAG 2064 He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685 GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA AAT GAA 2112 Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700 AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA GCA AAG 2160 Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720 GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA GCT TTA 2208 Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735 GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG TAT AAT 2256 Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750 CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT GAT GAT 2304 Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765 TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT AAT ATA 2352 Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780 AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT TCT ATC 2400 Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 79 ° 795 800 ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT CTT A A A ■> * * * He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lvs 80S 810 815 GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA ATT GGT ? * *<: Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 620 825 830 V CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT ACA GAT , , Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845 y ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA TTA TCT ,„, He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arq Leu Leu Ser 850 855 860 ACA TTT ACT GAA TAT ATT AAG TAA Thr Phe Thr Glu Tyr He Lys * 2616 865 870 (2) INFORMATION FOR SEQ ID NO 2 (l) SEQUENCE CHARACTERISTICS (A) LENGTH 872 amino acids (B) TYPE amino acid (D) TOPOLOGY linear (ii ) MOLECULE TYPE protein (xi) SEQUENCE DESCRIPTION SEQ ID NO 2 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480 He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 495 Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510 Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525 Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560 His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605 Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620 Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly Pro Ala 625 630 635 640 Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655 He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670 He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685 Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700 Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720 Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735 Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750 Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765 Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780 Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800 He Pro Tyr Gly Val Lys Arg Leu Glu Asp PKe Asp Ala Ser Leu Lys 805 810 815 Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 820 825 830 Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845 He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu Leu Ser 850 855 860 Thr Phe Thr Glu Tyr He Lys * 865 870 (2) INFORMATION FOR SEQ ID NO : 3: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2685 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY, linear (11) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2685 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 3 GGA TCC CCA GGA ATT CAT ATG ACG TCG ACG CGT CTG CAG AAG CTT CTA 48 Gly Ser Pro Gly He His Met Thr Ser Thr Arg Leu Gin Lys Leu Leu 1 10 15 GAA TTC GAG CTC CCG GGT ACC ATG GAG TTC GTG AAC AAG CAG TTC AAC 96 Glu Phe Glu Leu Pro Gly Thr Met Glu Phe Val Asn Lvs Gin Phe Asn 20 25 ' 30 TAT AAG GAC CCT GTA AAC GGT GTT GAC ATT GCC TAC ATC AAA ATT CCA 144 Tyr Lys Asp Pro Val Asn Gly Val Asp He Ala Tyr He Lvs He Pro 35 40 45 AAG TAC GGC CAG ATG CAG CCG GTG AAG GCT TTC AAG ATT CAT AAC AAA 192 Lys Tyr Gly Gin Met Gin Pro Val Lys Ala Phe Lys He His Asn Lys 50 55 60 ATC TGG GTT ATT CCG GAA CGC GAT ACA TTT ACG AAC CCG GAA GAA GGA 240 He Trp Val He Pro Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly 65 70 75 80 GAC TTG AAC CCG CCG CCG GAA GCA AAG CAG GTG CCA GTT TCA TAC TAC 288 Asp Leu Asn Pro Pro Pro Glu Ala Lys Gin Val Pro Val Ser Tyr Tyr 85 90 95 GAT TCA ACC TAT CTG AGC ACA GAC AAC GAG AAG GAT AAC TAC CTG AAG 336 Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys 100 105 110 GGA GTG ACC AAA TTA TTC GAG CGT ATT TAT TCC ACT GAC CTG GGC CGT 384 Gly Val Thr Lys Leu Phe Glu Arg He Tyr Ser Thr Asp Leu Gly Arg 115 120 125 ATG CTG CTG ACC TCA ATC GTC CGC GGA ATC CCA TTT TGG GGT GGC AGT 432 Met Leu Leu Thr Ser He Val Arg Gly He Pro Phe Trp Gly Gly Ser 130 135 140 ACC ATT GAC ACG GAG TTG AAG GTT ATT GAC ACT AAC TGC ATT AAC GTG 480 Thr He Asp Thr Glu Leu Lys Val He Asp Thr Asn Cys He Asn Val 145 150 155 160 ATC CAA CCA GAC GGT AGC TAC AGA TCT GAA GAA CTT AAC CTC GTA ATC 528 He Gin Pro Asp Gly Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val He 165 170 175 ATC GGG CCC TCC GCG GAC ATT ATC CAG TTT GAG TGC AAG AGC TTT GGC 576 He Gly Pro Ser Ala Asp He He Gin Phe Glu Cys Lys Ser Phe Gly 180 185 190 CAC GAA GTG TTG AAC CTG ACG CGT AAC GGT TAC GGC TCT ACT CAG TAC 624 His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gin Tyr 195 200 205 ATT CGT TTC AGC CCA GAC TTC ACG TTC GGT TTC GAG GAG AGC CTG GAG 672 He Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu 210 215 220 GTT GAT ACC AAC CCG CTG TTG GGT GCA GGC AAG TTC GCA ACT GAT CCA 720 Val Asp Thr Asn Pro Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro 225 230 235 240 GCG GTG ACC CTG GCA CAC GAG CTG ATC CAC GCC GGT CAT CGT CTG TAT 768 Ala Val Thr Leu Ala His Glu Leu He His Ala Glv His Arg Leu Tyr 245 250 ' 255 GGC ATT GCG ATT AAC CCG AAC CGC GTG TTC AAG GTT AAC ACC AAC GCC 816 Gly He Ala He Asn Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala 260 265 270 TAC TAC GAG ATG AGT GGT TTA GAA GTA AGC TTC GAG GAA CTG CGC ACG 864 Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr 275 280 285 TTC GGT GGC CAT GAT GCG AAG TTT ATC GAC AGC TTG CAG GAG AAC GAG 912 Phe Gly Gly His Asp Ala Lys Phe He Asp Ser Leu Gin Glu Asn Glu 290 295 300 TTC CGT CTG TAC TAC TAC AAC AAG TTT AAA GAT ATT GCA AGT ACA CTG 96 0 Phe Arg Leu Tyr Tyr Tyr Asn Lys Phe Lys Asp He Ala Ser Thr Leu 305 310 315 320 AAC AAG GCT AAG TCC ATT GTG GGT ACC ACT GCT TCA TTA CAG TAT ATG 1008 Asn Lys Ala Lys Ser He Val Gly Thr Thr Ala Ser Leu Gin Tyr Met 325 330 335 AAA AAT GTT TTT AAA GAG AAA TAT CTC CTA TCT GAA GAT ACA TCT GGA 1056 Lys Asn Val Phe Lys Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly 340 345 350 AAA TTT TCG GTA GAT AAA TTA AAA TTT GAT AAG TTA TAC AAA ATG TTA 110 4 Lys Phe Ser Val Asp Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu 355 360 365 ACA GAG ATT TAC ACA GAG GAT AAT TTT GTT AAG TTT TTT AAA GTA CTT 1152 Thr Glu He Tyr Thr Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu 370 375 380 AAC AGA AAA ACA TAT TTG AAT TTT GAT AAA GCC GTA TTT AAG ATA AAT 1200 Asn Arg Lys Thr Tyr Leu Asn Phe Asp Lys Ala Val Phe Lys He Asn 385 390 395 400 ATA GTA CCT AAG GTA AAT TAC ACA ATA TAT GAT GGA TTT AAT TTA AGA 1248 He Val Pro Lys Val Asn Tyr Thr He Tyr Asp Gly Phe Asn Leu Arg 405 410 415 AAT ACA AAT TTA GCA GCA AAC TTT AAT GGT CAA AAT ACA GAA ATT AAT 1296 Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gin Asn Thr Glu He Asn 420 425 430 AAT ATG AAT TTT ACT AAA CTA AAA AAT TTT ACT GGA TTG TTT GAA TTT 1344 Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe 435 440 445 TAT AAG TTG CTA TGT GTA AGA GGG ATA ATA ACT TCT AAA ACT AAA TCA 1392 Tyr Lys Leu Leu Cys Val Arg Gly He He Thr Ser Lys Thr Lys Ser 450 455 460 TTA GAT AAA GGA TAC AAT AAG GCA TTA AAT GAT TTA TGT ATC AAA GTT 1440 Leu Asp Lys Gly Tyr Asn Lys Ala Leu Asn Asp Leu Cys He Lys Val 465 470 475 480 AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT 1488 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu ASD Asn Phe Thr Asn 485 490 * 495 GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1536 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 500 505 510 GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC 158 4 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 515 520 525 TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA 1632 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 530 535 540 AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 168 0 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 545 550 555 560 CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT 1728 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lvs Tyr Thr Met Phe His Tyr 565 570 575 CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA 1776 Leu Arg Ala Gin Glu Phe Glu His Gly Lvs Ser Arg He Ala Leu Thr 580 585 590 AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT 1824 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 595 600 605 TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT 1872 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 610 615 620 ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA 1920 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 625 630 635 640 ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT 1968 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 645 650 655 ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA 2016 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 660 665 670 GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA 2064 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 675 680 685 GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT 2112 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 690 695 700 GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT 2160 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 705 710 715 720 GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA 2208 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 725 730 735 GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA 2256 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 740 745 750 AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT 2304 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 755 760 765 ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT 2352 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 770 775 780 ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA 2400 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 785 790 795 800 AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 2448 Asn Lvs Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 805 810 815 TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA 2496 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 820 825 830 GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT 254 4 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 835 840 845 AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT 2592 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 850 855 860 AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2640 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 865 870 875 880 GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA 2685 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 885 890 895 (2) INFORMATION FOR SEQ ID NO : 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 895 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Gly Ser Pro Gly He His Met Thr Ser Thr Arg Leu Gin Lys Leu Leu 1 5 10 15 Glu Phe Glu Leu Pro Gly Thr Met Glu Phe Val Asn Lys Gin Phe Asn 20 25 30 - Tyr Lys Asp Pro Val Asn Gly Val Asp He Ala Tyr He Lys He Pro 35 40 45 Lys Tyr Gly Gin Met Gin Pro Val Lys Ala Phe Lys He His Asn Lys 50 55 60 He Trp Val He Pro Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly 65 70 75 80 Asp Leu Asn Pro Pro Pro Glu Ala Lys Gin Val Pro Val Ser Tyr Tyr 85 90 95 Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys 100 105 * 110 Gly Val Thr Lys Leu Phe Glu Arg He Tyr Ser Thr Asp Leu Gly Arq 115 120 125 Met Leu Leu Thr Ser He Val Arg Gly He Pro Phe Trp Gly Gly Ser 130 135 140 Thr He Asp Thr Glu Leu Lys Val He Asp Thr Asn Cys He Asn Val 145 150 155 ' 160 He Gin Pro Asp Gly Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val He 165 170 175 He Gly Pro Ser Ala Asp He He Gin Phe Glu Cys Lys Ser Phe Gly 180 185 ' 190 His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr Glv Ser Thr Gin Tyr 195 200 * ' 205 He Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu 210 215 220 Val Asp Thr Asn Pro Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro 225 230 235 240 Ala Val Thr Leu Ala His Glu Leu He His Ala Gly His Arg Leu Tyr 245 250 255 Gly He Ala He Asn Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala 260 265 270 Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr 275 280 285 Phe Gly Gly His Asp Ala Lys Phe He Asp Ser Leu Gin Glu Asn Glu 290 295 300 Phe Arg Leu Tyr Tyr Tyr Asn Lys Phe Lys Asp He Ala Ser Thr Leu 305 310 315 320 Asn Lys Ala Lys Ser He Val Gly Thr Thr Ala Ser Leu Gin Tyr Met 325 330 335 Lys Asn Val Phe Lys Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly 3.40 345 350 Lys Phe Ser Val Asp Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu 355 360 365 Thr Glu He Tyr Thr Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu 370 375 380 Asn Arg Lys Thr Tyr Leu Asn Phe Asp Lys Ala Val Phe Lys He Asn 385 390 395 400 He Val Pro Lys Val Asn Tyr Thr He Tyr Asp Gly Phe Asn Leu Arg 405 410 415 Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gin Asn Thr Glu He Asn 420 425 430 Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe 435 440 445 Tyr Lys Leu Leu Cys Val Arg Gly He He Thr Ser Lys Thr Lys Ser 450 455 460 Leu Asp Lys Gly Tyr Asn Lys Ala Leu Asn Asp Leu Cys He Lvs V al 465 470 475 - 480 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 485 490 495 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 500 505 510 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 515 520 525 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 530 535 540 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arα P h < = 545 550 555 9 5g J Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 565 570 575 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 580 585 590 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 595 600 605 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 610 615 620 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 25 630 635 640 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 6 5 650 655 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 660 665 670 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 675 680 685 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 690 695 700 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He As p Asn 705 710 715 * 720 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tvr He 725 730 735 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Ar q 740 745 750 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 755 760 765 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 770 775 780 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 785 790 795 8 00 sn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 805 810 815 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 820 825 830 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 835 B40 845 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 850 855 860 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 865 B70 875 ' 880 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 885 890 895 (2) INFORMATION FOR SEQ ID NO : 5. (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2622 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY: linear (n) MOLECULE TYPE- DNA (genomic) (ix) FEATURE. (A) NAME/KEY: CDS (B) LOCATION: 1..2622 ( i ) SEQUENCE DESCRIPTION: SEQ ID NO : 5: GGA TCC ATG GAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA 48 Gly Ser Met Glu Phe Val Asn Lys Gin Phe Asn Tvr Lys Asp Pro Val 1 5 10 ' 15 AAC GGT GTT GAC ATT GCC TAC ATC AAA ATT CCA AAG TAC GGC CAG ATG 96 Asn Gly Val Asp He Ala Tyr He Lys He Pro Lys Tyr Gly Gin Met 20 25 30 CAG CCG GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG 144 Gin Pro Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro 35 40 45 GAA CGC GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG 192 Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro 50 55 60 CCG GAA GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG 240 Pro Glu Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu 65 70 75 80 AGC ACA GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA 288 Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu 85 90 95 TTC GAG CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA 336 Phe Glu Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser 100 105 110 ATC GTC CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG 384 He Val Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu 115 120 125 TTG AAG GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT 432 Leu Lys Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly 130 135 140 AGC TAC AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC rrr 480 Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala 145 15 ° 155 160 GAC ATT ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC 528 Asp He He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn 165 170 175 CTG ACG CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA 5 7 6 Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro 180 185 190 GAC TTC ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG 624 Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro 195 200 205 CTG TTG GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA 672 Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala 210 215 220 CAC GAG CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC 720 His Glu Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn 225 230 235 240 CCG AAC CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT 768 Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser 245 250 255 GGT TTA GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT 816 Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp 260 265 270 GCG AAG TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC 86 4 Ala Lys Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr 275 280 285 TAC AAC AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC 912 Tyr Asn Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser 290 295 300 ATT GTG GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA 960 He Val Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys 305 310 315 320 GAG AAA TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT 1008 Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp 325 330 335 AAA TTA AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA 1056 Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr 340 345 350 GAG GAT AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT 1104 Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr 355 360 365 TTG AAT TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA 1152 Leu Asn Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val 370 375 380 AAT TAC ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA 1200 Asn Tyr Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala 385 390 395 400 GCA AAC TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT 1248 Ala Asn Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr 405 410 415 AAA CTA AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT 1296 Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys 420 425 * 430 GTA AGA GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC 1344 Val Arg Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr 435 440 445 AAT AAG GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG 1392 Asn Lys Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu 450 455 460 TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA 1440 Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly 465 470 475 ' 480 GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT 1488 Glu Glu He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He 485 490 495 AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT 1536 Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn 500 505 510 GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC 1584 Glu Pro Glu Asn He Ser He Glu Asn Leu Ser Ser ASP He He Gly 515 520 525 CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG 1632 Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lvs 530 535 540 TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA 1680 Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu 545 550 555 560 TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA 1728 Phe Glu His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu 565 570 575 GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT 1776 Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr 580 585 590 GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG 1824 Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp 595 600 605 GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT 1872 Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser 610 615 620 ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA 1920 Thr Thr Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly 625 630 635 640 CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT 1968 Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly 645 650 655 GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG 2016 Ala Leu He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu 660 665 670 ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG 2064 He Ala He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala 675 680 685 AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA 2112 Asn Lys Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg 690 695 700 AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA 2160 Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu 705 710 715 720 GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA 2208 Ala Lys Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu 725 730 735 GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG 2256 Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin 740 745 750 TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT 2304 Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He 755 760 765 GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT 2352 Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He 770 775 780 AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT 2400 Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tvr Leu Met Asn 785 790 795 ' 800 TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT 2448 Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser 805 810 815 CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA 2496 Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu 820 825 830 ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT 2544 He Gly Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser 835 840 845 ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA 2592 Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu 850 855 860 TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA 2622 Leu Ser Thr Phe Thr Glu Tyr He Lys * 865 870 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERIS ICS: (A) LENGTH: 874 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6: Gly Ser Met Glu Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val 1 5 10 15 Asn Gly Val Asp He Ala Tyr He Lys He Pro Lys Tyr Gly Gin Met 20 25 30 Gin Pro Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro 35 40 45 Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro 50 55 60 Pro Glu Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu 65 70 75 80 Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu 85 90 95 Phe Glu Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser 100 105 110 He Val Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu 115 120 125 Leu Lys Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly 130 135 140 Ser Tvr Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala 145 ' 150 155 160 Asp He He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn 165 170 175 Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro 180 185 190 Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro 195 200 205 Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala 210 215 220 His Glu Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn 225 230 235 240 Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser 245 250 255 Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp 260 265 270 Ala Lys Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr 275 . 280 285 Tyr Asn Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser 290 295 300 He Val Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys 305 310 315 320 Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys-Phe Ser Val Asp 325 330 335 Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr 340 345 350 Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr 355 360 365 Leu Asn Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val 370 375 380 Asn Tyr Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala 385 390 395 400 Ala Asn Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr 405 410 415 Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys 420 425 * 430 Val Arg Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr 435 440 445 Asn Lys Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu 450 455 460 Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn AΞD Leu Asn Lys Gly 465 470 475 " 480 Glu Glu He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He 485 490 495 Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn 500 505 510 Glu Pro Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly 515 520 525 Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys 530 535 540 Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu 545 550 555 560 Phe Glu His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu 565 570 575 Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr 580 585 590 Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp 595 600 605 Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser 610 615 620 Thr Thr Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly 625 630 635 640 Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly 645 650 655 Ala Leu He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu 660 665 670 He Ala He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala 675 680 685 Asn Lys Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg 690 695 700 Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu 705 710 715 720 Ala Lys Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu 725 730 735 Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin 740 745 750 Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He 755 760 765 Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He 770 775 780 Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tvr Leu Met Asn 785 790 795 ' 800 Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser 805 810 815 Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu 820 825 830 He Gly Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser 835 840 845 Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu 850 855 860 Leu Ser Thr Phe Thr Glu Tyr He Lys * 865 870 (2) INFORMATION FOR SEQ ID NO ■ 7 (l) SEQUENCE CHARACTERISTICS: (A) LENGTH- 2613 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS- double (D) TOPOLOGY: linear (ii ) MOLECULE TYPE- DNA (genomic) (IX) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2613 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7: ATG CCA TTT GTT AAT AAA CAA TTT AAT TAT AAA GAT CCT GTA AAT GGT 46 Met Pro Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 GTT GAT ATT GCT TAT ATA AAA ATT CCA AAT GCA GGA CAA ATG CAA CCA 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 GTA AAA GCT TTT AAA ATT CAT AAT AAA ATA TGG GTT ATT CCA GAA AGA 144 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 GAT ACA TTT ACA AAT CCT GAA GAA GGA GAT TTA AAT CCA CCA CCA GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 GCA AAA CAA GTT CCA GTT TCA TAT TAT GAT TCA ACA TAT TTA AGT ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 GAT AAT GAA AAA GAT AAT TAT TTA AAG GGA GTT ACA AAA TTA TTT GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 AGA ATT TAT TCA ACT GAT CTT GGA AGA ATG TTG TTA ACA TCA ATA GTA 33f i Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 HO AGG GGA ATA CCA TTT TGG GGT GGA AGT ACA ATA GAT ACA GAA TTA AAA 3 84 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lvs 115 120 125 GTT ATT GAT ACT AAT TGT ATT AAT GTG ATA CAA CCA GAT GGT AGT TAT 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 AGA TCA GAA GAA CTT AAT CTA GTA ATA ATA GGA CCC TCA GCT GAT ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 ATA CAG TTT GAA TGT AAA AGC TTT GGA CAT GAA GTT TTG AAT CTT ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 CGA AAT GGT TAT GGC TCT ACT CAA TAC ATT AGA TTT AGC CCA GAT TTT 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 ACA TTT GGT TTT GAG GAG TCA CTT GAA GTT GAT ACA AAT CCT CTT TTA 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 GGT GCA GGC AAA TTT GCT ACA GAT CCA GCA GTA ACA TTA GCA CAT GAA 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 CTT ATA CAT GCT GGA CAT AGA TTA TAT GGA ATA GCA ATT AAT CCA AAT 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 AGG GTT TTT AAA GTA AAT ACT AAT GCC TAT TAT GAA ATG AGT GGG TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 GAA GTA AGC TTT GAG GAA CTT AGA ACA TTT GGG GGA CAT GAT GCA AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 TTT ATA GAT AGT TTA CAG GAA AAC GAA TTT CGT CTA TAT TAT TAT AAT 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 AAG TTT AAA GAT ATA GCA AGT ACA CTT AAT AAA GCT AAA TCA ATA GTA 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 GGT ACT ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lvs 05 310 315 320 TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1 200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG TTT TTT 1392 Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460 AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA GAA GAA 1440 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480 ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT AGT TTA 1488 He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 495 GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT GAA CCT 1536 Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510 GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC CAA TTA 1584 Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525 GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG TAT GAG 1632 Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540 TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA TTT GAA 1680 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560 CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA GCA TTA 1728 His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 5JZ5 TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT GTA AAG 1776 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590 AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG GTA GAA 1824 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605 CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT ACT ACG 1872 Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620 GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA CCT GCT 1920 Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly Pro Ala 625 630 635 640 TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT GCT TTA 1968 Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655 ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG ATT GCA 2016 He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670 ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG AAT AAG 206 4 He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685 GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA AAT GAA 2112 Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700 AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA GCA AAG 2160 Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720 GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA GCT TTA 2208 Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735 GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG TAT AAT 2256 Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750 CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT GAT GAT 2304 Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765 TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT AAT ATA 2352 Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780 AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT TCT ATG 2400 Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800 ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT CTT AAA 2448 He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815 GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA ATT GGT 2496 Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 820 825 830 CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT ACA GAT 2544 Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845 ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA TTA TCT 2592 He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu Leu Ser 850 855 860 ACA TTT ACT GAA TAT ATT AAG 2613 Thr Phe Thr Glu Tyr He Lys 865 870 (2) INFORMATION FOR SEQ ID NO : 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 871 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 8: Met Pro Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 " 215 220 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 39 ° 395 400 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lvs Leu 405 410 4i5 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arα 420 425 4^ 0 9 Gly He lie Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 J Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp ASD Leu Phe Phe 450 455 460 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 47 ° 475 480 He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 4g5 Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510 Glu Asn lie Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525 Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560 His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lvs 580 585 590 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605 Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620 Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly Pro Ala 625 630 635 640 Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655 He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670 He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685 Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700 Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720 Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735 Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750 Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765 Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780 Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800 He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815 Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 820 825 830 Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845 He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu Leu Ser 850 855 860 Thr Phe Thr Glu Tyr He Lys 865 870 (2) INFORMATION FOR SEQ ID NO : 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2628 base pairs (B) TYPE: nucleic acid ( C ) STRANDEDNESS : double (D) TOPOLOGY : linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATIO :1..2628 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 9: ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC A CA Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 5 70 75 80 GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG P AR Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 33 6 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 3A4 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 4 3? Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tvr 130 135 140 y 7 AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tvr Asn 275 280 285 AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 129 6 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 13 44 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 AGC GCT GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG 1392 Ser Ala Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp 450 455 460 GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT 1440 Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn 465 470 475 480 AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA 1488 Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu 485 490 495 AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT 1536 Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe 500 505 510 GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT 1584 Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He 515 520 525 ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA 1632 He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly 530 535 540 AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT 1680 Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala 545 550 555 560 CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT 1728 Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val 565 570 575 AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA 1776 Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser 580 585 590 GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA 1824 Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu 595 600 605 - 57 - GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT ACC . s Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Sp Glϊ τ£ Ser Sϊ ϋlu 615 620 GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT C CA TAT Val Ser Thr Thr Asp Lys He Ala Asp He Thr l J He He Pro ϊyr 1920 6 5 63 ° 635 6 4 0 ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys Asp AsJ Phe 1968 650 655 GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TT A CAA T TT a ™ Val Gly Ala Leu He Phe Ser Gly Ala Val lie Leu Ξu Git Hi J£ 660 665 670 CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr 2064 675 680 685 ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser 211; 690 695 700 AA A AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn 2160 705 710 715 720 TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met 2208 725 730 735 AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn 2256 740 745 750 TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe 2304 755 760 765 AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala 2352 770 775 780 ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu 2400 785 790 795 800 ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp 2448 805 810 B15 GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly 2496 820 825 830 ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr 2544 835 840 845 CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin 2592 850 855 860 AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 2628 865 870 875 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 876 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 Ser Ala Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp 450 455 460 Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn 465 470 475 480 Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu 485 490 495 Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe 500 505 510 Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He 515 520 525 He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly 530 535 540 Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala 545 550 555 560 Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val 565 570 575 Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe-Phe Ser Ser 580 585 590 Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu 595 600 605 Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu 610 615 620 Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He He Pro Tyr 625 630 635 640 He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe 645 650 655 Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu Glu Phe He 660 665 670 Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr 675 680 685 He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser 690 695 700 Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn 705 710 715 720 Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met 725 730 735 Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn 740 745 750 Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe 755 760 765 Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala 770 775 780 Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu 785 790 795 800 Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp 805 810 815 Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly 820 825 830 Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr 835 840 845 Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin 850 855 860 Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 865 870 875 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2637 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2637 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GA A err Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arα 144 35 40 4 5 a GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG C CC P Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 192 50 55 60 GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC A CA Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 240 65 70 75 80 GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GA G Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 288 85 90 9 5 CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 336 100 105 110 CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lvs 384 115 120 125 y GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TT C Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro As p Phe 576 180 185 190 ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TT C Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 624 195 200 205 GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG K ? Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gl y Leu 768 245 250 255 GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lvs 816 260 265 270 TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 864 275 280 285 A ™A™G T-.T.-T-. G sj AnTx A Λ T i T i GuCι_AΛ AnGuTi AΛC»_AΛ Cl_TlG-j AΛAACL AAAAGU GGC C TT AAAAGG TTCCCC AATTTT GGTTGG q Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys A Allaa Lys Ser He Val 290 295 300 GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT 1392 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460 AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT 1440 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1488 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495 GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC 1536 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510 TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA 1584 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525 AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 1632 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540 CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT 1680 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA 1728 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575 AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT 1776 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590 TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT 1824 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA 1872 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620 ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT 1920 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640 ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA 1968 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655 GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA 2016 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670 GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT 206 4 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685 GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT 2112 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700 GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA 2160 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720 GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA 2208 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735 AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT 2256 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750 ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT 2304 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765 ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA 2352 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780 AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 2400 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800 TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA 2448 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT 2496 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830 AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT 2544 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845 AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2592 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860 GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA 2637 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 865 870 875 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 879 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 6 4 0 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lvs Val 835 840 845 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 865 870 875 (2) INFORMATION FOR SEQ ID NO: 13: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2862 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2862 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 336 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 384 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT 1392 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460 AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT 1 40 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1488 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495 GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC 1536 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510 TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA 1584 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525 AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 1632 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540 CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT 1680 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lvs Tyr Thr Met Phe His Tyr 545 550 " 555 560 CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA 1728 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575 AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT 1776 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 595 590 TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT 1824 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA 1872 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620 ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT 1920 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640 ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA 1968 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655 GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA 2016 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670 GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT 2064 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685 GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT 2112 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700 GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA 2160 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720 GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA 2208 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735 AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT 2256 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750 ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT 2304 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765 ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA 2352 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780 AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 2400 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800 TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA 2448 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT 2496 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830 AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT 2544 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845 AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2592 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860 GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TCT AGG 2640 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Arg 865 870 875 880 CCT GGA CCG GAG ACG CTC TGC GGG GCT GAG CTG GTG GAT GCT CTT CAG 2688 Pro Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gin 885 890 895 TTC GTG TGT GGA GAC AGG GGC TTT TAT TTC AAC AAG CCC ACA GGG TAT 2736 Phe Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr 900 905 910 GGC TCC AGC AGT CGG AGG GCG CCT CAG ACA GGT ATC GTG GAT GAG TGC 2784 Gly Ser Ser Ser Arg Arg Ala Pro Gin Thr Gly He Val Asp Glu Cys 915 920 925 TGC TTC CGG AGC TGT GAT CTA AGG AGG CTG GAG ATG TAT TGC GCA CCC 2832 Cys Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro 930 935 940 CTC AAG CCT GCC AAG TCA GCT GAA GCT TAG 2862 Leu Lys Pro Ala Lys Ser Ala Glu Ala * 945 950 (2) INFORMATION FOR SEQ ID NO: 14: (l) SEQUENCE CHARACTERISTICS (A) LENGTH: 954 amino acids (B) TYPE, ammo acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Arg 865 870 875 880 Pro Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gin 885 890 895 Phe Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr 900 905 910 Gly Ser Ser Ser Arg Arg Ala Pro Gin Thr Gly He Val Asp Glu Cys 915 920 925 Cys Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro 930 935 940 Leu Lys Pro Ala Lys Ser Ala Glu Ala * 945 950 (2) INFORMATION FOR SEQ ID NO . 15- (l) SEQUENCE CHARACTERISTICS: (A) LENGTH 2724 base pairs (B) TYPE, nucleic acid (C) STRANDEDNESS. double (D) TOPOLOGY, linear (n) MOLECULE TYPE: DNA (genomic) (IX) FEATURE: (A) NAME/KEY CDS (B) LOCATION: 1..2724 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15. ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 336 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 384 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro A S P Phe 180 185 190 ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 13 4 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT 1392 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460 AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT 1440 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1488 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495 GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC 1536 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510 TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA 1584 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525 AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 1632 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540 CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT 1680 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA 1728 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575 AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT 1776 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590 TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT 1824 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA 1872 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620 ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT 1920 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640 ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA 1968 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655 GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA 2016 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670 GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT 2064 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685 GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT 2112 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700 GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA 2160 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720 GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA 2208 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735 AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT 2256 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750 ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT 2304 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765 ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA 2352 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780 AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 2400 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800 TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA 2448 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT 2496 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830 AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT 2544 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845 AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2592 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860 GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TCT AGG 26 0 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Arg 865 870 875 880 CCT CAA TCT AAA GTT AAA AGA CAA ATA TTT TCA GGC TAT CAA TCT GAT 2688 Pro Gin Ser Lys Val Lys Arg Gin He Phe Ser Gly Tyr Gin Ser Asp 885 890 895 ATT GAT ACA CAT AAT AGA ATT AAG GAT GAA TTA TGA 2724 He Asp Thr His Asn Arg He Lys Asp Glu Leu * 900 905 (2) INFORMATION FOR SEQ ID NO : 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 908 ammo acids (B) TYPE: ammo acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 16: Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Arg 865 870 875 880 Pro Gin Ser Lys Val Lys Arg Gin He Phe Ser Gly Tyr Gin Ser Asp 885 890 895 He Asp Thr His Asn Arg He Lys Asp Glu Leu * 900 905 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3042 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:!..3042 ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 17: ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 1 92 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tvr Leu Ser Thr 65 70 75 " 80 GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 336 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 384 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lvs Val Asn Tyr 370 375 380 ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr LyS Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT 1392 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460 AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT 1440 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1488 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495 GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC 1536 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510 TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA 1584 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525 AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 1632 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540 CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT 1680 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA 1728 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575 AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT 17 7 6 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590 TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT 1824 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA 1872 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620 ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT 1920 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640 ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA 1968 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655 GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA 2016 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670 GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT 2064 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685 GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT 2112 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700 GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA 2160 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720 GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA 2208 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735 AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT 2256 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750 ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT 2304 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765 ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA 2352 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780 AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 2400 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800 TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA 2448 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT 2496 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830 AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT 2544 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845 AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2592 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860 GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TCA GGC 2640 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Gly 865 870 875 880 CTG AAT TCC CCG GGT GCA GCT CAT TAT GCG CAA CAC GAT GAA GCC GTA 2688 Leu Asn Ser Pro Gly Ala Ala His Tyr Ala Gin His Asp Glu Ala Val 885 890 895 GAC AAC AAA TTC AAC AAA GAA CAA CAA AAC GCG TTC TAT GAG ATC TTA 2736 Asp Asn Lys Phe Asn Lys Glu Gin Gin Asn Ala Phe Tyr Glu He Leu 900 905 910 CAT TTA CCT AAC TTA AAC GAA GAA CAA CGA AAC GCC TTC ATC CAA AGT 2784 His Leu Pro Asn Leu Asn Glu Glu Gin Arg Asn Ala Phe He Gin Ser 915 920 925 TTA AAA GAT GAC CCA AGC CAA AGC GCT AAC CTT TTA GCA GAA GCT AAA 2832 Leu Lys Asp Asp Pro Ser Gin Ser Ala Asn Leu Leu Ala Glu Ala Lys 930 935 940 AAG CTA AAT GAT GCT CAG GCG CCG AAA GTA GAC AAC AAA TTC AAC AAA 2880 Lvs Leu Asn Asp Ala Gin Ala Pro Lys Val Asp Asn Lys Phe Asn Lys 945 950 955 960 GAA CAA CAA AAC GCG TTC TAT GAG ATC TTA CAT TTA CCT AAC TTA AAC 2928 Glu Gin Gin Asn Ala Phe Tyr Glu He Leu His Leu Pro Asn Leu Asn 965 970 975 GAA GAA CAA CGA AAC GCC TTC ATC CAA AGT TTA AAA GAT GAC CCA AGC 2976 Glu Glu Gin Arg Asn Ala Phe He Gin Ser Leu Lys Asp Asp Pro Ser 980 985 990 CAA AGC GCT AAC CTT TTA GCA GAA GCT AAA AAG CTA AAT GAT GCT CAG 3024 Gin Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gin 995 1000 1005 GCG CCG AAA GTA GAC TAG 3042 Ala Pro Lys Val Asp * 1010 (2) INFORMATION FOR SEQ ID NO: 18: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1014 ammo acids (B) TYPE: ammo acid (D) TOPOLOGY, linear (ii) MOLECULE TYPE: protein (Xl) SEQUENCE DESCRIPTION. SEQ ID NO: 18: Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala ieu 675 680 685 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tvr Asp 820 825 830 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Gly 865 870 875 880 Leu Asn Ser Pro Gly Ala Ala His Tyr Ala Gin His Asp Glu Ala Val 885 890 895 Asp Asn Lys Phe Asn Lys Glu Gin Gin Asn Ala Phe Tyr Glu He Leu 900 905 910 His Leu Pro Asn Leu Asn Glu Glu Gin Arg Asn Ala Phe He Gin Ser 915 920 925 Leu Lys Asp Asp Pro Ser Gin Ser Ala Asn Leu Leu Ala Glu Ala Lys 930 935 940 Lys Leu Asn Asp Ala Gin Ala Pro Lys Val Asp Asn Lys Phe Asn Lys 945 950 955 960 Glu Gin Gin Asn Ala Phe Tyr Glu He Leu His Leu Pro Asn Leu Asn 965 970 975 Glu Glu Gin Arg Asn Ala Phe He Gin Ser Leu Lys Asp Asp Pro Ser 980 985 990 Gin Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gin 995 1000 1005 Ala Pro Lys Val Asp * 1010 (2) INFORMATION FOR SEQ ~ D NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3509 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (n) MOLECULE TYPE: DNA (genomic) (IX) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..3509 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: ATG CCA GTT ACA ATA AAT AAT TTT AAT TAT AAT GAT CCT ATT GAT AAT 48 Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15 AAT AAT ATT ATT ATG ATG GAG CCT CCA TTT GCG AGA GGT ACG GGG AGA 96 Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30 TAT TAT AAA GCT TTT AAA ATC ACA GAT CGT ATT TGG ATA ATA CCG GAA 144 Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45 AGA TAT ACT TTT GGA TAT AAA CCT GAG GAT TTT AAT AAA AGT TCC GGT 192 Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60 ATT TTT AAT AGA GAT GTT TGT GAA TAT TAT GAT CCA GAT TAC TTA AAT 240 He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80 ACT AAT GAT AAA AAG AAT ATA TTT TTA CAA ACA ATG ATC AAG TTA TTT 288 Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95 AAT AGA ATC AAA TCA AAA CCA TTG GGT GAA AAG TTA TTA GAG ATG ATT 336 Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110 ATA AAT GGT ATA CCT TAT CTT GGA GAT AGA CGT GTT CCA CTC GAA GAG 384 He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125 TTT AAC ACA AAC ATT GCT AGT GTA ACT GTT AAT AAA TTA ATC AGT AAT 432 Phe Asn Thr Asn He Ala Ser Val Thr Val Asn Lys Leu He Ser Asn 130 135 140 CCA GGA GAA GTG GAG CGA AAA AAA GGT ATT TTC GCA AAT TTA ATA ATA 480 Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160 TTT GGA CCT GGG CCA GTT TTA AAT GAA AAT GAG ACT ATA GAT ATA GGT 528 Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175 ATA CAA AAT CAT TTT GCA TCA AGG GAA GGC TTC GGG GGT ATA ATG CAA 576 He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190 ATG AAG TTT TGC CCA GAA TAT GTA AGC GTA TTT AAT AAT GTT CAA GAA 624 Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205 AAC AAA GGC GCA AGT ATA TTT AAT AGA CGT GGA TAT TTT TCA GAT CCA 672 Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220 GCC TTG ATA TTA ATG CAT GAA CTT ATA CAT GTT TTA CAT GGA TTA TAT 720 Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 240 GGC ATT AAA GTA GAT GAT TTA CCA ATT GTA CCA AAT GAA AAA AAA TTT 768 Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe 245 250 255 TTT ATG CAA TCT ACA GAT GCT ATA CAG GCA GAA GAA CTA TAT ACA TTT 816 Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270 GGA GGA CAA GAT CCC AGC ATC ATA ACT CCT TCT ACG GAT AAA AGT ATC 864 Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285 TAT GAT AAA GTT TTG CAA AAT TTT AGA GGG ATA GTT GAT AGA CTT AAC 912 Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300 AAG GTT TTA GTT TGC ATA TCA GAT CCT AAC ATT AAT ATT AAT ATA TAT 960 Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320 AAA AAT AAA TTT AAA GAT AAA TAT AAA TTC GTT GAA GAT TCT GAG GGA 1008 Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335 AAA TAT AGT ATA GAT GTA GAA AGT TTT GAT AAA TTA TAT AAA AGC TTA 1056 Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350 ATG TTT GGT TTT ACA GAA ACT AAT ATA GCA GAA AAT TAT AAA ATA AAA 1104 Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365 ACT AGA GCT TCT TAT TTT AGT GAT TCC TTA CCA CCA GTA AAA ATA AAA 1152 Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380 AAT TTA TTA GAT AAT GAA ATC TAT ACT ATA GAG GAA GGG TTT AAT ATA 1200 Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400 TCT GAT AAA GAT ATG GAA AAA GAA TAT AGA GGT CAG AAT AAA GCT ATA 1248 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He 405 410 415 AAT AAA CAA GCT TAT GAA GAA ATT AGC AAG GAG CAT TTG GCT GTA TAT 1296 Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430 AAG ATA CAA ATG TGT AAA AGT GTT AAA GCT CCA GGA ATA TGT ATT GAT 1344 Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445 GTT GAT AAT GAA GAT TTG TTC TTT ATA GCT GAT AAA AAT AGT TTT TCA 1392 Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser 450 455 460 GAT GAT TTA TCT AAA AAC GAA AGA ATA GAA TAT AAT ACA CAG AGT AAT 1440 Asp Asp Leu Ser Lys Asn Glu Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480 TAT ATA GAA AAT GAC TTC CCT ATA AAT GAA TTA ATT TTA GAT ACT GAT 1488 Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp 485 490 495 TTA ATA AGT AAA ATA GAA TTA CCA AGT GAA AAT ACA GAA TCA CTT ACT 1536 Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510 GAT TTT AAT GTA GAT GTT CCA GTA TAT GAA AAA CAA CCC GCT ATA AAA 1584 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525 AAA ATT TTT ACA GAT GAA AAT ACC ATC TTT CAA TAT TTA TAC TCT CAG 1632 Lys He Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540 ACA TTT CCT CTA GAT ATA AGA GAT ATA AGT TTA ACA TCT TCA TTT GAT 1680 Thr Phe Pro Leu Asp He Arg Asp He Ser Leu Thr Ser Ser Phe Asp 545 550 555 560 GAT GCA TTA TTA TTT TCT AAC AAA GTT TAT TCA TTT TTT TCT ATG GAT 1728 Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp 565 570 575 TAT ATT AAA ACT GCT AAT AAA GTG GTA GAA GCA GGA TTA TTT GCA GGT 1776 Tyr He Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly 580 585 590 TGG GTG AAA CAG ATA GTA AAT GAT TTT GTA ATC GAA GCT AAT AAA AGC 1824 Trp Val Lys Gin He Val Asn Asp Phe Val He Glu Ala Asn Lys Ser 595 600 605 AAT ACT ATG GAT AAA ATT GCA GAT ATA TCT CTA ATT GTT CCT TAT ATA 1872 Asn Thr Met Asp Lys He Ala Asp He Ser Leu He Val Pro Tyr He 610 615 620 GGA TTA GCT TTA AAT GTA GGA AAT GAA ACA GCT AAA GGA AAT TTT GAA 1920 Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu 625 630 635 640 AAT GCT TTT GAG ATT GCA GGA GCC AGT ATT CTA CTA GAA TTT ATA CCA 1968 Asn Ala Phe Glu He Ala Gly Ala Ser He Leu Leu Glu Phe He Pro 645 650 655 GAA CTT TTA ATA CCT GTA GTT GGA GCC TTT TTA TTA GAA TCA TAT ATT 2016 Glu Leu Leu He Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr He 660 665 670 GAC AAT AAA AAT AAA ATT ATT AAA ACA ATA GAT AAT GCT TTA ACT AAA 2064 Asp Asn Lys Asn Lys He He Lys Thr He Asp Asn Ala Leu Thr Lys 675 680 685 AGA AAT GAA AAA TGG AGT GAT ATG TAC GGA TTA ATA GTA GCG CAA TGG 2112 Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu He Val Ala Gin Trp 690 695 700 CTC TCA ACA GTT AAT ACT CAA TTT TAT ACA ATA AAA GAG GGA ATG TAT 2160 Leu Ser Thr Val Asn Thr Gin Phe Tyr Thr He Lys Glu Gly Met Tyr 705 710 715 720 AAG GCT TTA AAT TAT CAA GCA CAA GCA TTG GAA GAA ATA ATA AAA TAC 2208 Lys Ala Leu Asn Tyr Gin Ala Gin Ala Leu Glu Glu He He Lys Tyr 725 730 735 AGA TAT AAT ATA TAT TCT GAA AAA GAA AAG TCA AAT ATT AAC ATC GAT 2256 Arg Tyr Asn He Tyr Ser Glu Lys Glu Lys Ser Asn He Asn He Asp 740 745 750 TTT AAT GAT ATA AAT TCT AAA CTT AAT GAG GGT ATT AAC CAA GCT ATA 2304 Phe Asn Asp He Asn Ser Lys Leu Asn Glu Gly He Asn Gin Ala He 755 760 765 GAT AAT ATA AAT AAT TTT ATA AAT GGA TGT TCT GTA TCA TAT TTA ATG 2352 Asp Asn He Asn Asn Phe He Asn Gly Cys Ser Val Ser Tyr Leu Met 770 775 780 AAA AAA ATG ATT CCA TTA GCT GTA GAA AAA TTA CTA GAC TTT GAT AAT 2400 Lys Lys Met He Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn 785 790 795 800 ACT CTC AAA AAA AAT TTG TTA AAT TAT ATA GAT GAA AAT AAA TTA TAT 2448 Thr Leu Lys Lys Asn Leu Leu Asn Tyr He Asp Glu Asn Lys Leu Tyr 805 810 815 TTG ATT GGA AGT GCA GAA TAT GAA AAA TCA AAA GTA AAT AAA TAC TTG 2496 Leu He Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu 820 825 830 AAA ACC ATT ATG CCG TTT GAT CTT TCA ATA TAT ACC AAT GAT ACA ATA 2544 Lys Thr He Met Pro Phe Asp Leu Ser He Tyr Thr Asn Asp Thr He 835 840 845 CTA ATA GAA ATG TTT AAT AAA TAT AAT AGC GAA ATT TTA AAT AAT ATT 2592 Leu He Glu Met Phe Asn Lys Tyr Asn Ser Glu He Leu Asn Asn He 850 855 860 ATC TTA AAT TTA AGA TAT AAG GAT AAT AAT TTA ATA GAT TTA TCA GGA 2640 He Leu Asn Leu Arg Tyr Lys Asp Asn Asn Leu He Asp Leu Ser Gly 865 870 875 880 TAT GGG GCA AAG GTA GAG GTA TAT GAT GGA GTC GAG CTT AAT GAT AAA 2688 Tyr Gly Ala Lys Val Glu Val Tyr Asp Gly Val Glu Leu Asn Asp Lys 885 890 895 AAT CAA TTT AAA TTA ACT AGT TCA GCA AAT AGT AAG ATT AGA GTG ACT 2736 Asn Gin Phe Lys Leu Thr Ser Ser Ala Asn Ser Lys He Arg Val Thr 900 905 910 CAA AAT CAG AAT ATC ATA TTT AAT AGT GTG TTC CTT GAT TTT AGC GTT 278 4 Gin Asn Gin Asn He He Phe Asn Ser Val Phe Leu Asp Phe Ser Val 915 920 925 AGC TTT TGG ATA AGA ATA CCT AAA TAT AAG AAT GAT GGT ATA CAA AAT 2832 Ser Phe Trp He Arg He Pro Lys Tyr Lys Asn Asp Gly He Gin Asn 930 935 940 TAT ATT CAT AAT GAA TAT ACA ATA ATT AAT TGT ATG AAA AAT AAT TCG 2880 Tyr He His Asn Glu Tyr Thr He He Asn Cys Met Lys Asn Asn Ser 945 950 955 960 GGC TGG AAA ATA TCT ATT AGG GGT AAT AGG ATA ATA TGG ACT TTA ATT 2928 Gly Trp Lys He Ser He Arg Gly Asn Arg He He Trp Thr Leu He 965 970 975 GAT ATA AAT GGA AAA ACC AAA TCG GTA TTT TTT GAA TAT AAC ATA AGA 2976 Asp He Asn Gly Lys Thr Lys Ser Val Phe Phe Glu Tyr Asn He Arg 980 985 990 GAA GAT ATA TCA GAG TAT ATA AAT AGA TGG TTT TTT GTA ACT ATT ACT 3024 Glu Asp He Ser Glu Tyr He Asn Arg Trp Phe Phe Val Thr He Thr 995 1000 1005 AAT AAT TTG AAT AAC GCT AAA ATT TAT ATT AAT GGT AAG CTA GAA TCA 3072 Asn Asn Leu Asn Asn Ala Lys He Tyr He Asn Gly Lys Leu Glu Ser 1010 1015 1020 AAT ACA GAT ATT AAA GAT ATA AGA GAA GTT ATT GCT AAT GGT GAA ATA 3120 Asn Thr Asp He Lys Asp He Arg Glu Val He Ala Asn Gly Glu He 1025 1030 1035 1040 ATA TTT AAA TTA GAT GGT GAT ATA GAT AGA ACA CAA TTT ATT TGG ATG 3168 He Phe Lys Leu Asp Gly Asp He Asp Arg Thr Gin Phe He Trp Met 1045 1050 1055 AAA TAT TTC AGT ATT TTT AAT ACG GAA TTA AGT CAA TCA AAT ATT GAA 3216 Lys Tyr Phe Ser He Phe Asn Thr Glu Leu Ser Gin Ser Asn He Glu 1060 1065 1070 GAA AGA TAT AAA ATT CAA TCA TAT AGC GAA TAT TTA AAA GAT TTT TGG 3264 Glu Arg Tyr Lys He Gin Ser Tyr Ser Glu Tyr Leu Lys Asp Phe Trp 1075 1080 1085 GGA AAT CCT TTA ATG TAC AAT AAA GAA TAT TAT ATG TTT AAT GCG GGG 3312 Gly Asn Pro Leu Met Tyr Asn Lys Glu Tyr Tyr Met Phe Asn Ala Gly 1090 1095 1100 AAT AAA AAT TCA TAT ATT AAA CTA AAG AAA GAT TCA CCT GTA GGT GAA 3360 Asn Lys Asn Ser Tyr He Lys Leu Lys Lys Asp Ser Pro Val Gly Glu 1105 1110 1115 1120 ATT TTA ACA CGT AGC AAA TAT AAT CAA AAT TCT AAA TAT ATA AAT TAT 3408 He Leu Thr Arg Ser Lys Tyr Asn Gin Asn Ser Lys Tyr He Asn Tyr 1125 1130 1135 AGA GAT TTA TAT ATT GGA GAA AAA TTT ATT ATA AGA AGA AAG TCA AAT 3456 Arg Asp Leu Tyr He Gly Glu Lys Phe He He Arg Arg Lys Ser Asn 1140 1145 1150 TCT CAA TCT ATA AAT GAT GAT ATA GTT AGA AAA GAA GAT TAT ATA TAT 3504 Ser Gin Ser He Asn Asp Asp He Val Arg Lys Glu Asp Tyr He Tyr 1155 1160 1165 CTA GA 3509 Leu (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1169 ammo acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15 Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30 Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45 Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60 He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80 Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95 Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110 He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125 Phe Asn Thr Asn He Ala Ser Val Thr Val Asn Lys Leu He Ser Asn 130 135 140 Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160 Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175 He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190 Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205 Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220 Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 240 Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe 245 250 255 Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270 Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285 Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300 Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320 Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335 Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350 Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365 Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380 Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He 405 410 415 Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430 Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445 Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser Asp Asp Leu Ser Lys Asn Glu Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480 Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp 485 490 495 Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525 Lys He Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540 Thr Phe Pro Leu Asp He Arg Asp He Ser Leu Thr Ser Ser Phe Asp 545 550 555 560 Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp 565 570 575 Tyr He Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly 580 585 590 Trp Val Lys Gin He Val Asn Asp Phe Val He Glu Ala Asn Lys Ser 595 600 605 Asn Thr Met Asp Lys He Ala Asp He Ser Leu He Val Pro Tyr He 610 615 620 Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu 625 630 635 640 Asn Ala Phe Glu He Ala Gly Ala Ser He Leu Leu Glu Phe He Pro 645 650 655 Glu Leu Leu He Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr He 660 665 670 Asp Asn Lys Asn Lys He He Lys Thr He Asp Asn Ala Leu Thr Lys 675 680 685 Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu He Val Ala Gin Trp 690 695 700 Leu Ser Thr Val Asn Thr Gin Phe Tyr Thr He Lys Glu Gly Met Tyr 705 710 715 720 Lys Ala Leu Asn Tyr Gin Ala Gin Ala Leu Glu Glu He He Lys Tyr 725 730 735 Arg Tyr Asn He Tyr Ser Glu Lys Glu Lys Ser Asn He Asn He Asp 740 745 750 Phe Asn Asp He Asn Ser Lys Leu Asn Glu Gly He Asn Gin Ala He 755 760 765 Asp Asn He Asn Asn Phe He Asn Gly Cys Ser Val Ser Tyr Leu Met 770 775 780 Lys Lys Met He Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn 785 790 795 800 Thr Leu Lys Lys Asn Leu Leu Asn Tyr He Asp Glu Asn Lys Leu Tyr 805 810 815 Leu He Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu 820 825 830 Lys Thr He Met Pro Phe Asp Leu Ser He Tyr Thr Asn Asp Thr He 835 840 845 Leu He Glu Met Phe Asn Lys Tyr Asn Ser Glu He Leu Asn Asn He 850 855 860 He Leu Asn Leu Arg Tyr Lys Asp Asn Asn Leu He Asp Leu Ser Gly 865 870 875 880 Tyr Gly Ala Lys Val Glu Val Tyr Asp Gly Val Glu Leu Asn Asp Lys 885 890 895 Asn Gin Phe Lys Leu Thr Ser Ser Ala Asn Ser Lys He Arg Val Thr 900 905 910 Gin Asn Gin Asn He He Phe Asn Ser Val Phe Leu Asp Phe Ser Val 915 920 925 Ser Phe Trp He Arg He Pro Lys Tyr Lys Asn Asp Gly He Gin Asn 930 935 940 Tyr He His Asn Glu Tyr Thr He He Asn Cys Met Lys Asn Asn Ser 945 950 955 960 Gly Trp Lys He Ser He Arg Gly Asn Arg He He Trp Thr Leu He 965 970 975 Asp He Asn Gly Lys Thr Lys Ser Val Phe Phe Glu Tyr Asn He Arg 980 985 990 Glu Asp He Ser Glu Tyr He Asn Arg Trp Phe Phe Val Thr He Thr 995 1000 1005 Asn Asn Leu Asn Asn Ala Lys He Tyr He Asn Gly Lys Leu Glu Ser 1010 1015 1020 Asn Thr Asp He Lys Asp He Arg Glu Val He Ala Asn Gly Glu He 1025 1030 1035 1040 He Phe Lys Leu Asp Gly Asp He Asp Arg Thr Gin Phe He Trp Met 1045 1050 1055 Lys Tyr Phe Ser He Phe Asn Thr Glu Leu Ser Gin Ser Asn He Glu 1060 1065 1070 Glu Arg Tyr Lys He Gin Ser Tyr Ser Glu Tyr Leu Lys Asp Phe Trp 1075 1080 1085 Gly Asn Pro Leu Met Tyr Asn Lys Glu Tyr Tyr Met Phe Asn Ala Gly 1090 1095 1100 Asn Lys Asn Ser Tyr He Lys Leu Lys Lys Asp Ser Pro Val Gly Glu 1105 1110 1115 1120 He Leu Thr Arg Ser Lys Tyr Asn Gin Asn Ser Lys Tyr He Asn Tyr 1125 1130 1135 Arg Asp Leu Tyr He Gly Glu Lys Phe He He Arg Arg Lys Ser Asn 1140 1145 1150 Ser Gin Ser He Asn Asp Asp He Val Arg Lys Glu Asp Tyr He Tyr 1155 1160 1165 Leu (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2574 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) ( ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..2574 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: ATG CCA GTT ACA ATA AAT AAT TTT AAT TAT AAT GAT CCT ATT GAT AAT 48 Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15 AAT AAT ATT ATT ATG ATG GAG CCT CCA TTT GCG AGA GGT ACG GGG AGA 96 Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30 TAT TAT AAA GCT TTT AAA ATC ACA GAT CGT ATT TGG ATA ATA CCG GAA 144 Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45 AGA TAT ACT TTT GGA TAT AAA CCT GAG GAT TTT AAT AAA AGT TCC GGT 192 Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60 ATT TTT AAT AGA GAT GTT TGT GAA TAT TAT GAT CCA GAT TAC TTA AAT 240 He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80 ACT AAT GAT AAA AAG AAT ATA TTT TTA CAA ACA ATG ATC AAG TTA TTT 288 Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95 AAT AGA ATC AAA TCA AAA CCA TTG GGT GAA AAG TTA TTA GAG ATG ATT 336 Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110 ATA AAT GGT ATA CCT TAT CTT GGA GAT AGA CGT GTT CCA CTC GAA GAG 384 He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125 TTT AAC ACA AAC ATT GCT AGT GTA ACT GTT AAT AAA TTA ATC AGT AAT 432 Phe Asn Thr Asn He Ala Ser Val Thr Val Asn Lys Leu He Ser Asn 130 135 140 CCA GGA GAA GTG GAG CGA AAA AAA GGT ATT TTC GCA AAT TTA ATA ATA 480 Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160 TTT GGA CCT GGG CCA GTT TTA AAT GAA AAT GAG ACT ATA GAT ATA GGT 528 Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175 ATA CAA AAT CAT " TTT GCA TCA AGG GAA GGC TTC GGG GGT ATA ATG CAA 576 He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190 ATG AAG TTT TGC CCA GAA TAT GTA AGC GTA TTT AAT AAT GTT CAA GAA 624 Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205 AAC AAA GGC GCA AGT ATA TTT AAT AGA CGT GGA TAT TTT TCA GAT CCA 672 Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220 GCC TTG ATA TTA ATG CAT GAA CTT ATA CAT GTT TTA CAT GGA TTA TAT 720 Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 240 GGC ATT AAA GTA GAT GAT TTA CCA ATT GTA CCA AAT GAA AAA AAA TTT 768 Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe 245 250 255 TTT ATG CAA TCT ACA GAT GCT ATA CAG GCA GAA GAA CTA TAT ACA TTT 816 Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270 GGA GGA CAA GAT CCC AGC ATC ATA ACT CCT TCT ACG GAT AAA AGT ATC 86 4 Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285 TAT GAT AAA GTT TTG CAA AAT TTT AGA GGG ATA GTT GAT AGA CTT AAC 912 Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300 AAG GTT TTA GTT TGC ATA TCA GAT CCT AAC ATT AAT ATT AAT ATA TAT 960 Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320 AAA AAT AAA TTT AAA GAT AAA TAT AAA TTC GTT GAA GAT TCT GAG GGA 1008 Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335 AAA TAT AGT ATA GAT GTA GAA AGT TTT GAT AAA TTA TAT AAA AGC TTA 1056 Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350 ATG TTT GGT TTT ACA GAA ACT AAT ATA GCA GAA AAT TAT AAA ATA AAA 1104 Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365 ACT AGA GCT TCT TAT TTT AGT GAT TCC TTA CCA CCA GTA AAA ATA AAA 1152 Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380 AAT TTA TTA GAT AAT GAA ATC TAT ACT ATA GAG GAA GGG TTT AAT ATA 1200 Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400 TCT GAT AAA GAT ATG GAA AAA GAA TAT AGA GGT CAG AAT AAA GCT ATA 1248 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He 405 410 415 AAT AAA CAA GCT TAT GAA GAA ATT AGC AAG GAG CAT TTG GCT GTA TAT 1296 Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430 AAG ATA CAA ATG TGT AAA AGT GTT AAA GCT CCA GGA ATA TGT ATT GAT 1344 Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445 GTT GAT AAT GAA GAT TTG TTC TTT ATA GCT GAT AAA AAT AGT TTT TCA 1392 Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser 450 455 460 GAT GAT TTA TCT AAA AAC GAA AGA ATA GAA TAT AAT ACA CAG AGT AAT 1440 Asp Asp Leu Ser Lys Asn Glu Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480 TAT ATA GAA AAT GAC TTC CCT ATA AAT GAA TTA ATT TTA GAT ACT GAT 1488 Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp 485 490 495 TTA ATA AGT AAA ATA GAA TTA CCA AGT GAA AAT ACA GAA TCA CTT ACT 1536 Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510 GAT TTT AAT GTA GAT GTT CCA GTA TAT GAA AAA CAA CCC GCT ATA AAA 1584 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525 AAA ATT TTT ACA GAT GAA AAT ACC ATC TTT CAA TAT TTA TAC TCT CAG 1632 Lys He Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540 ACA TTT CCT CTA GAT ATA AGA GAT ATA AGT TTA ACA TCT TCA TTT GAT 1680 Thr Phe Pro Leu Asp He Arg Asp He Ser Leu Thr Ser Ser Phe Asp 545 550 555 560 GAT GCA TTA TTA TTT TCT AAC AAA GTT TAT TCA TTT TTT TCT ATG GAT 1728 Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp 565 570 575 TAT ATT AAA ACT GCT AAT AAA GTG GTA GAA GCA GGA TTA TTT GCA GGT 1776 Tyr He Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly 580 585 590 TGG GTG AAA CAG ATA GTA AAT GAT TTT GTA ATC GAA GCT AAT AAA AGC 1824 Trp Val Lys Gin He Val Asn Asp Phe Val He Glu Ala Asn Lys Ser 595 600 605 AAT ACT ATG GAT AAA ATT GCA GAT ATA TCT CTA ATT GTT CCT TAT ATA 1872 Asn Thr Met Asp Lys He Ala Asp He Ser Leu He Val Pro Tyr He 610 615 620 GGA TTA GCT TTA AAT GTA GGA AAT GAA ACA GCT AAA GGA AAT TTT GAA 1920 Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu 625 630 635 640 AAT GCT TTT GAG ATT GCA GGA GCC AGT ATT CTA CTA GAA TTT ATA CCA 1968 Asn Ala Phe Glu He Ala Gly Ala Ser He Leu Leu Glu Phe He Pro 645 650 655 GAA CTT TTA ATA CCT GTA GTT GGA GCC TTT TTA TTA GAA TCA TAT ATT 2016 Glu Leu Leu He Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr He 660 665 670 GAC AAT AAA AAT AAA ATT ATT AAA ACA ATA GAT AAT GCT TTA ACT AAA 2064 Asp Asn Lys Asn Lys He He Lys Thr He Asp Asn Ala Leu Thr Lys 675 680 685 AGA AAT GAA AAA TGG AGT GAT ATG TAC GGA TTA ATA GTA GCG CAA TGG 2112 Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu He Val Ala Gin Trp 690 695 700 CTC TCA ACA GTT AAT ACT CAA TTT TAT ACA ATA AAA GAG GGA ATG TAT 2160 Leu Ser Thr Val Asn Thr Gin Phe Tyr Thr He Lys Glu Gly Met Tyr 705 710 715 720 AAG GCT TTA AAT TAT CAA GCA CAA GCA TTG GAA GAA ATA ATA AAA TAC 2208 Lys Ala Leu Asn Tyr Gin Ala Gin Ala Leu Glu Glu He He Lys Tyr 725 730 735 AGA TAT AAT ATA TAT TCT GAA AAA GAA AAG TCA AAT ATT AAC ATC GAT 2256 Arg Tyr Asn He Tyr Ser Glu Lys Glu Lys Ser Asn He Asn He Asp 740 745 750 TTT AAT GAT ATA AAT TCT AAA CTT AAT GAG GGT ATT AAC CAA GCT ATA 2304 Phe Asn Asp He Asn Ser Lys Leu Asn Glu Gly He Asn Gin Ala He 755 760 765 GAT AAT ATA AAT AAT TTT ATA AAT GGA TGT TCT GTA TCA TAT TTA ATG 2352 Asp Asn He Asn Asn Phe He Asn Gly Cys Ser Val Ser Tyr Leu Met 770 775 780 AAA AAA ATG ATT CCA TTA GCT GTA GAA AAA TTA CTA GAC TTT GAT AAT 2400 Lys Lys Met He Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn 785 790 795 800 ACT CTC AAA AAA AAT TTG TTA AAT TAT ATA GAT GAA AAT AAA TTA TAT 2448 Thr Leu Lys Lys Asn Leu Leu Asn Tyr He Asp Glu Asn Lys Leu Tyr 805 810 815 TTG ATT GGA AGT GCA GAA TAT GAA AAA TCA AAA GTA AAT AAA TAC TTG 2496 Leu He Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu 820 825 830 AAA ACC ATT ATG CCG TTT GAT CTT TCA ATA TAT ACC AAT GAT ACA ATA 2544 Lys Thr He Met Pro Phe Asp Leu Ser He Tyr Thr Asn Asp Thr He 835 840 845 CTA ATA GAA ATG TTT AAT AAA TAT AAT AGC 2574 Leu He Glu Met Phe Asn Lys Tyr Asn Ser 850 855 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 858 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15 Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30 Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45 Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60 He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80 Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95 Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110 He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125 Phe Asn Thr Asn He Ala Ser Val Thr Val Asn Lys Leu He Ser Asn 130 135 140 Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160 Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175 He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190 Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205 Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220 Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 240 Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe 245 250 255 Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270 Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285 Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300 Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320 Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335 Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350 Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365 Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380 Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He 405 410 415 Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430 Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445 Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser 450 455 460 Asp Asp Leu Ser Lys Asn Glu " Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480 Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp 485 490 495 Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525 Lys lie Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540 Thr Phe Pro Leu Asp He Arg Asp He Ser Leu Thr Ser Ser Phe Asp 545 550 555 560 Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp 565 570 575 Tyr He Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly 580 585 590 Trp Val Lys Gin He Val Asn Asp Phe Val He Glu Ala Asn Lys Ser 595 600 605 Asn Thr Met Asp Lys He Ala Asp He Ser Leu He Val Pro Tyr He 610 615 620 Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu 625 630 635 640 Asn Ala Phe Glu He Ala Gly Ala Ser He Leu Leu Glu Phe He Pro 645 650 655 Glu Leu Leu He Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr He 660 665 670 Asp Asn Lys Asn Lys He He Lys Thr He Asp Asn Ala Leu Thr Lys 675 680 685 Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu He Val Ala Gin Trp 690 695 700 Leu Ser Thr Val Asn Thr Gin Phe Tyr Thr He Lys Glu Gly Met Tyr 705 710 715 720 Lys Ala Leu Asn Tyr Gin Ala Gin Ala Leu Glu Glu He He Lys Tyr 725 730 735 Arg Tyr Asn He Tyr Ser Glu Lys Glu Lys Ser Asn He Asn He Asp 740 745 750 Phe Asn Asp He Asn Ser Lys Leu Asn Glu Gly He Asn Gin Ala He 755 760 765 Asp Asn He Asn Asn Phe He Asn Gly Cys Ser Val Ser Tyr Leu Met 770 775 780 Lys Lys Met He Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn 785 790 795 800 Thr Leu Lys Lys Asn Leu Leu Asn Tyr He Asp Glu Asn Lys Leu Tyr 805 810 815 Leu He Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu 820 825 830 Lys Thr He Met Pro Phe Asp Leu Ser He Tyr Thr Asn Asp Thr He 835 840 845 Leu He Glu Met Phe Asn Lys Tyr Asn Ser 850 855 (2) INFORMATION FOR SEQ ID NO : 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1644 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (11 ) MOLECULE TYPE DNA (genomic) (ix) FEATURE (A) NAME/KEY CDS (B) LOCATION 1 1644 (xi ) SEQUENCE DESCRIPTION SEQ ID NO 23 ATG CCA GTT ACA ATA AAT AAT TTT AAT TAT AAT GAT CCT ATT GAT AAT 48 Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15 AAT AAT ATT ATT ATG ATG GAG CCT CCA TTT GCG AGA GGT ACG GGG AGA 96 Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30 TAT TAT AAA GCT TTT AAA ATC ACA GAT CGT ATT TGG ATA ATA CCG GAA 144 Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45 AGA TAT ACT TTT GGA TAT AAA CCT GAG GAT TTT AAT AAA AGT TCC GGT 192 Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60 ATT TTT AAT AGA GAT GTT TGT GAA TAT TAT GAT CCA GAT TAC TTA AAT 240 He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80 ACT AAT GAT AAA AAG AAT ATA TTT TTA CAA ACA ATG ATC AAG TTA TTT 288 Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95 AAT AGA ATC AAA TCA AAA CCA TTG GGT GAA AAG TTA TTA GAG ATG ATT 336 Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110 ATA AAT GGT ATA CCT TAT CTT GGA GAT AGA CGT GTT CCA CTC GAA GAG 384 He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125 TTT AAC ACA AAC ATT GCT AGT GTA ACT GTT AAT AAA TTA ATC AGT AAT 432 Phe Asn Thr Asn He Ala Ser Val Thr Val Asn Lys Leu He Ser Asn 130 135 140 CCA GGA GAA GTG GAG CGA AAA AAA GGT ATT TTC GCA AAT TTA ATA ATA 480 Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160 TTT GGA CCT GGG CCA GTT TTA AAT GAA AAT GAG ACT ATA GAT ATA GGT 528 Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175 ATA CAA AAT CAT TTT GCA TCA AGG GAA GGC TTC GGG GGT ATA ATG CAA 576 He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190 ATG AAG TTT TGC CCA GAA TAT GTA AGC GTA TTT AAT AAT GTT CAA GAA 624 Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205 AAC AAA GGC GCA AGT ATA TTT AAT AGA CGT GGA TAT TTT TCA GAT CCA 672 Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220 GCC TTG ATA TTA ATG CAT GAA CTT ATA CAT GTT TTA CAT GGA TTA TAT 720 Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 ' 240 GGC ATT AAA GTA GAT GAT TTA CCA ATT GTA CCA AAT GAA AAA AAA TTT 768 Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe 245 250 255 TTT ATG CAA TCT ACA GAT GCT ATA CAG GCA GAA GAA CTA TAT ACA TTT 816 Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270 GGA GGA CAA GAT CCC AGC ATC ATA ACT CCT TCT ACG GAT AAA AGT ATC 864 Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285 TAT GAT AAA GTT TTG CAA AAT TTT AGA GGG ATA GTT GAT AGA CTT AAC 912 Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300 AAG GTT TTA GTT TGC ATA TCA GAT CCT AAC ATT AAT ATT AAT ATA TAT 960 Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320 AAA AAT AAA TTT AAA GAT AAA TAT AAA TTC GTT GAA GAT TCT GAG GGA 1008 Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335 AAA TAT AGT ATA GAT GTA GAA AGT TTT GAT AAA TTA TAT AAA AGC TTA 1056 Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350 ATG TTT GGT TTT ACA GAA ACT AAT ATA GCA GAA AAT TAT AAA ATA AAA 1104 Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365 ACT AGA GCT TCT TAT TTT AGT GAT TCC TTA CCA CCA GTA AAA ATA AAA 1152 Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380 AAT TTA TTA GAT AAT GAA ATC TAT ACT ATA GAG GAA GGG TTT AAT ATA 1200 Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400 TCT GAT AAA GAT ATG GAA AAA GAA TAT AGA GGT CAG AAT AAA GCT ATA 1248 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He 405 410 415 AAT AAA CAA GCT TAT GAA GAA ATT AGC AAG GAG CAT TTG GCT GTA TAT 1296 Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430 AAG ATA CAA ATG TGT AAA AGT GTT AAA GCT CCA GGA ATA TGT ATT GAT 1344 Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445 GTT GAT AAT GAA GAT TTG TTC TTT ATA GCT GAT AAA AAT AGT TTT TCA 1392 Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser 450 455 460 GAT GAT TTA TCT AAA AAC GAA AGA ATA GAA TAT AAT ACA CAG AGT AAT 1440 Asp Asp Leu Ser Lys Asn Glu Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480 TAT ATA GAA AAT GAC TTC CCT ATA AAT GAA TTA ATT TTA GAT ACT GAT 1488 Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp 485 490 495 TTA ATA AGT AAA ATA GAA TTA CCA AGT GAA AAT ACA GAA TCA CTT ACT 1536 Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510 GAT TTT AAT GTA GAT GTT CCA GTA TAT GAA AAA CAA CCC GCT ATA AAA 1584 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525 AAA ATT TTT ACA GAT GAA AAT ACC ATC TTT CAA TAT TTA TAC TCT CAG 1632 Lys He Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540 ACA TTT CCT CTA 1644 Thr Phe Pro Leu 545 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 548 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 24: Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15 Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30 Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45 Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60 He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80 Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95 Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110 He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125 Phe Asn Thr Asn He Ala Ser Val Thr Val Asπ Lys Leu He Ser Asn 130 135 140 Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160 Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175 He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190 Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205 Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220 Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 240 Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe 245 250 255 Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270 Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285 Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300 Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320 Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335 Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350 Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365 Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380 Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He 405 410 415 Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430 Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445 Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser 450 455 460 Asp Asp Leu Ser Lys Asn Glu Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480 Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp 485 490 495 Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525 Lys He Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540 Thr Phe Pro Leu 545 (2) INFORMATION FOR SEQ ID NO : 25: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2616 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (n) MOLECULE TYPE. DNA (genomic) (ix) FEATURE. (A) NAME/KEY: CDS (B) LOCATION: 1..2616 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25. ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 336 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 384 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG TTT TTT 1392 Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460 AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA GAA GAA 1440 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480 ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT AGT TTA 1488 He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 495 GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT GAA CCT 1536 Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510 GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC CAA TTA 1584 Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525 GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG TAT GAG 1632 Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540 TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA TTT GAA 1680 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560 CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA GCA TTA 1728 His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575 TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT GTA AAG 1776 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590 AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG GTA GAA 1824 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605 CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT ACT ACG 1872 Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620 GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA CCT GCT 1920 Asp Lys He Ala Asp He Thr He He He Pro Tyr He Glv Pro Ala 625 630 635 ' 640 TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT GCT TTA 1968 Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655 ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG ATT GCA 2016 He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670 ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG AAT AAG 2064 He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685 GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA AAT GAA 2112 Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700 AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA GCA AAG 2160 Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720 GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA GCT TTA 2208 Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735 GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG TAT AAT 2256 Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750 CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT GAT GAT 2304 Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765 TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT AAT ATA 2352 Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780 AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT TCT ATG 2400 Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800 ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT CTT AAA 2448 He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815 GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA ATT GGT 2496 Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 820 825 830 CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT ACA GAT 2544 Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845 ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA TTA TCT 2592 He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu Leu Ser 850 855 860 ACA TTT ACT GAA TAT ATT AAG TAA 2616 Thr Phe Thr Glu Tyr He Lys * 865 870 (2) INFORMATION FOR SEQ ID NO : 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 872 ammo acids (B) TYPE: ammo acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 Val Lys Ala Phe Lys He His Asn Lys He Trp Val lie Pro Glu Arg 35 40 45 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480 He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 495 Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510 Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525 Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560 His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605 Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620 Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly Pro Ala 625 630 635 640 Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655 He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670 He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685 Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700 Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720 Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735 Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750 Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765 Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780 Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800 He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815 Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 820 825 830 Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845 He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu Leu Ser 850 855 860 Thr Phe Thr Glu Tyr He Lys * 865 870 (2) INFORMATION FOR SEQ ID NO : 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2574 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear ( i i ) MOLECULE TYPE : DNA ( genomic ) ( xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 27 : ATGCCGGTTA CCATCAACAA CTTCAACTAC AACGACCCGA TCGACAACAA CAACATCATC 60 ATGATGGAAC CGCCGTTCGC ACGTGGTACC GGTCGTTACT ACAAGGCTTT CAAGATCACC 120 GACCGTATCT GGATCATCCC GGAACGTTAC ACCTTCGGTT ACAAACCTGA GGACTTCAAC 180 AAGAGTAGCG GGATTTTCAA TCGTGACGTC TGCGAGTACT ATGATCCAGA TTATCTGAAT 240 ACCAACGATA AGAAGAACAT ATTCCTTCAG ACTATGATCA AGTTATTTAA TAGAATCAAA 300 TCAAAACCAT TGGGTGAAAA GTTATTAGAG ATGATTATAA ATGGTATACC TTATCTTGGA 360 GATAGACGTG TTCCACTCGA AGAGTTTAAC ACAAACATTG CTAGTGTAAC TGTTAATAAA 420 TTAATCAGTA ATCCAGGAGA AGTGGAGCGA AAAAAAGGTA TTTTCGCAAA TTTAATAATA 480 TTTGGACCTG GGCCAGTTTT AAATGAAAAT GAGACTATAG ATATAGGTAT ACAAAATCAT 540 TTTGCATCAA GGGAAGGCTT CGGGGGTATA ATGCAAATGA AGTTTTGCCC AGAATATGTA 600 AGCGTATTTA ATAATGTTCA AGAAAACAAA GGCGCAAGTA TATTTAATAG ACGTGGATAT 660 TTTTCAGATC CAGCCTTGAT ATTAATGCAT GAACTTATAC ATGTTTTACA TGGATTATAT 720 GGCATTAAAG TAGATGATTT ACCAATTGTA CCAAATGAAA AAAAATTTTT TATGCAATCT 780 ACAGATGCTA TACAGGCAGA AGAACTATAT ACATTTGGAG GACAAGATCC CAGCATCATA 840 ACTCCTTCTA CGGATAAAAG TATCTATGAT AAAGTTTTGC AAAATTTTAG AGGGATAGTT 900 GATAGACTTA ACAAGGTTTT AGTTTGCATA TCAGATCCTA ACATTAATAT TAATATATAT 960 AAAAATAAAT TTAAAGATAA ATATAAATTC GTTGAAGATT CTGAGGGAAA ATATAGTATA 1020 GATGTAGAAA GTTTTGATAA ATTATATAAA AGCTTAATGT TTGGTTTTAC AGAAACTAAT 1080 ATAGCAGAAA ATTATAAAAT AAAAACTAGA GCTTCTTATT TTAGTGATTC CTTACCACCA 1140 GTAAAAATAA AAAATTTATT AGATAATGAA ATCTATACTA TAGAGGAAGG GTTTAATATA 1200 TCTGATAAAG ATATGGAAAA AGAATATAGA GGTCAGAATA AAGCTATAAA TAAACAAGCT 1260 TATGAAGAAA TTAGCAAGGA GCATTTGGCT GTATATAAGA TACAAATGTG TAAAAGTGTT 1320 AAAGCTCCAG GAATATGTAT TGATGTTGAT AATGAAGATT TGTTCTTTAT AGCTGATAAA 1380 AATAGTTTTT CAGATGATTT ATCTAAAAAC GAAAGAATAG AATATAATAC ACAGAGTAAT 1440 TATATAGAAA ATGACTTCCC TATAAATGAA TTAATTTTAG ATACTGATTT AATAAGTAAA 1500 ATAGAATTAC CAAGTGAAAA TACAGAATCA CTTACTGATT TTAATGTAGA TGTTCCAGTA 1560 TATGAAAAAC AACCCGCTAT AAAAAAAATT TTTACAGATG AAAATACCAT CTTTCAATAT 1620 TTATACTCTC AGACATTTCC TCTAGATATA AGAGATATAA GTTTAACATC TTCATTTGAT 1680 GATGCATTAT TATTTTCTAA CAAAGTTTAT TCATTTTTTT CTATGGATTA TATTAAAACT 1740 GCTAATAAAG TGGTAGAAGC AGGATTATTT GCAGGTTGGG TGAAACAGAT AGTAAATGAT 1800 TTTGTAATCG AAGCTAATAA AAGCAATACT ATGGATAAAA TTGCAGATAT ATCTCTAATT 1860 GTTCCTTATA TAGGATTAGC TTTAAATGTA GGAAATGAAA CAGCTAAAGG AAATTTTGAA 1920 AATGCTTTTG AGATTGCAGG AGCCAGTATT CTACTAGAAT TTATACCAGA ACTTTTAATA 1980 CCTGTAGTTG GAGCCTTTTT ATTAGAATCA TATATTGACA ATAAAAATAA AATTATTAAA 2040 ACAATAGATA ATGCTTTAAC TAAAAGAAAT GAAAAATGGA GTGATATGTA CGGATTAATA 2100 GTAGCGCAAT GGCTCTCAAC AGTTAATACT CAATTTTATA CAATAAAAGA GGGAATGTAT 2160 AAGGCTTTAA ATTATCAAGC ACAAGCATTG GAAGAAATAA TAAAATACAG ATATAATATA 2220 TATTCTGAAA AAGAAAAGTC AAATATTAAC ATCGATTTTA ATGATATAAA TTCTAAACTT 2280 AATGAGGGTA TTAACCAAGC TATAGATAAT ATAAATAATT TTATAAATGG ATGTTCTGTA 2340 TCATATTTAA TGAAAAAAAT GATTCCATTA GCTGTAGAAA AATTACTAGA CTTTGATAAT 2400 ACTCTCAAAA AAAATTTGTT AAATTA ATA GATGAAAATA AATTATATTT GATTGGAAGT 2460 GCAGAATATG AAAAATCAAA AGTAAATAAA TACTTGAAAA CCATTATGCC GTTTGATCTT 2520 TCAATATATA CCAATGATAC AATACTAATA GAAATGTTTA ATAAATATAA TAGC 2574 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2574 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: ATGCCAGTTA CAATAAATAA TTTTAATTAT AATGATCCTA TTGATAATAA TAATATTATT 60 ATGATGGAGC CTCCATTTGC GAGAGGTACG GGGAGATATT ATAAAGCTTT TAAAATCACA 120 GATCGTATTT GGATAATACC GGAAAGATAT ACTTTTGGAT ATAAACCTGA GGATTTTAAT 180 AAAAGTTCCG GTATTTTTAA TAGAGATGTT TGTGAATATT ATGATCCAGA TTACTTAAAT 240 ACTAATGATA AAAAGAATAT ATTTTTACAA ACAATGATCA AGTTATTTAA TAGAATCAAA 300 TCAAAACCAT TGGGTGAAAA GTTATTAGAG ATGATTATAA ATGGTATACC TTATCTTGGA 360 GATAGACGTG TTCCACTCGA AGAGTTTAAC ACAAACATTG CTAGTGTAAC TGTTAATAAA 420 TTAATCAGTA ATCCAGGAGA AGTGGAGCGA AAAAAAGGTA TTTTCGCAAA TTTAATAATA 4 80 TTTGGACCTG GGCCAGTTTT AAATGAAAAT GAGACTATAG ATATAGGTAT ACAAAATCAT 540 TTTGCATCAA GGGAAGGCTT CGGGGGTATA ATGCAAATGA AGTTTTGCCC AGAATATGTA 600 AGCGTATTTA ATAATGTTCA AGAAAACAAA GGCGCAAGTA TATTTAATAG ACGTGGATAT 660 TTTTCAGATC CAGCCTTGAT ATTAATGCAT GAACTCATCC ACGTCCTCCA CGGTCTCTAC 720 GGTATCAAAG TAGACGACCT CCCGATCGTC CCGAACGAAA AAAAATTCTT CATGCAGAGC 780 ACCGACGCAA TCCAGGCAGA AGAACTCTAC ACCTTCGGTG GTCAGGACCC GAGCATCATC 840 ACCCCGAGCA CCGACAAAAG CATCTACGAC AAAGTCCTCC AGAACTTCCG TGGTATCGTC 900 GACCGTCTCA ACAAAGTCCT CGTCTGCATC AGCGACCCGA ACATCAACAT CAACATCTAC 960 AAAAACAAAT TCAAAGACAA ATACAAATTC GTCGAAGACA GCGAAGGTAA ATACAGCATC 1020 GACGTCGAGA GCTTCGACAA ACTCTACAAA AGCCTCATGT TCGGTTTCAC CGAAACCAAC 1080 ATCGCAGAAA ACTACAAAAT CAAAACCCGT GCAAGCTACT TCAGCGACAG CCTCCCGCCG 1140 GTCAAAATCA AAAACCTCCT CGACAACGAA ATCTACACCA TCGAAGAAGG TTTCAACATC 1200 AGCGACAAAG ACATGGAAAA AGAATACCGT GGTCAGAACA AAGCAATCAA CAAACAAGCT 1260 TACGAAGAAA TCAGCAAAGA ACACCTCGCA GTCTACAAAA TCCAGATGTG CAAAAGCGTC 1320 AAAGCACCGG GTATCTGCAT CGACGTTGAC AACGAAGACC TCTTCTTCAT CGCAGACAAA 1380 AACAGCTTCA GCGACGACCT CAGCAAAAAC GAACGTATCG AATACAACAC CCAGAGCAAC 1440 TACATCGAAA ACGACTTCCC GATCAACGAA CTCATCCTCG ACACCGACCT CATCAGCAAA 1500 ATCGAACTCC CGAGCGAAAA CACCGAAAGC CTCACCGACT TCAACGTTGA CGTCCCGGTC 1560 TACGAAAAAC AGCCGGCAAT CAAAAAAATC TTCACCGACG AAAACACCAT CTTCCAGTAC 1620 CTCTACAGCC AGACCTTCCC GCTAGATATA AGAGATATAA GTTTAACATC TTCATTTGAT 1680 GATGCATTAT TATTTTCTAA CAAAGTTTAT TCATTTTTTT CTATGGATTA TATTAAAACT 1740 GCTAATAAAG TGGTAGAAGC AGGATTATTT GCAGGTTGGG TGAAACAGAT AGTAAATGAT 1800 TTTGTAATCG AAGCTAATAA AAGCAATACT ATGGATAAAA TTGCAGATAT ATCTCTAATT 1860 GTTCCTTATA TAGGATTAGC TTTAAATGTA GGAAATGAAA CAGCTAAAGG AAATTTTGAA 1920 AATGCTTTTG AGATTGCAGG AGCCAGTATT CTACTAGAAT TTATACCAGA ACTTTTAATA 1980 CCTGTAGTTG GAGCCTTTTT ATTAGAATCA TATATTGACA ATAAAAATAA AATTATTAAA 2040 ACAATAGATA ATGCTTTAAC TAAAAGAAAT GAAAAATGGA GTGATATGTA CGGATTAATA 2100 GTAGCGCAAT GGCTCTCAAC AGTTAATACT CAATTTTATA CAATAAAAGA GGGAATGTAT 2160 AAGGCTTTAA ATTATCAAGC ACAAGCATTG GAAGAAATAA TAAAATACAG ATATAATATA 2220 TATTCTGAAA AAGAAAAGTC AAATATTAAC ATCGATTTTA ATGATATAAA TTCTAAACTT 2280 AATGAGGGTA TTAACCAAGC TATAGATAAT ATAAATAATT TTATAAATGG ATGTTCTGTA 2340 TCATATTTAA TGAAAAAAAT GATTCCATTA GCTGTAGAAA AATTACTAGA CTTTGATAAT 2400 ACTCTCAAAA AAAATTTGTT AAATTATATA GATGAAAATA AATTATATTT GATTGGAAGT 2460 GCAGAATATG AAAAATCAAA AGTAAATAAA TACTTGAAAA CCATTATGCC GTTTGATCTT 2520 TCAATATATA CCAATGATAC AATACTAATA GAAATGTTTA ATAAATATAA TAGC 2574

Claims: CLAIMS 1 . A polypeptide comprising first and second domains, wherein said first domain is adapted to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and wherein said second domain is adapted (i) to translocate the polypeptide into a cell or (ii) to increase the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both to translocate the polypeptide into a cell and to increase the solubility of the polypeptide compared to the solubility of the first domain on its own, said polypeptide being free of clostridial neurotoxin and free of clostridial neurotoxin precursor that can be converted into toxin by proteolytic action . 2. A polypeptide according to Claim 1 wherein said first domain comprises a clostridial toxin light chain. 3. A polypeptide according to Claim 1 wherein said first domain comprises a fragment or variant of a clostridial toxin light chain. 4. A polypeptide according to Claim 2 or 3 wherein the clostridial toxin is a botulinum toxin. 5. A polypeptide according to any preceding claim wherein the first domain exhibits endopeptidase activity specific for a substrate selected from one or more of SNAP-25, synaptobrevin/VAMP and syntaxin. 6. A polypeptide according to any preceding claim wherein said second domain comprises a clostridial toxin heavy chain H N portion. 7. A polypeptide according to any of Claims 1 -5 wherein said second domain comprises a fragment or variant of a clostridial toxin heavy chain H N portion. 8. A polypeptide according to Claim 6 or 7 wherein the clostridial toxin is a botulinum toxin. 9. A polypeptide according to any of Claims 1 -8 further comprising a third domain adapted for binding of the polypeptide to a cell, by binding of the third domain directly to a cell or by binding of the third domain to a ligand or to ligands that bind to a cell. 10. A polypeptide according to Claim 9 wherein said third domain is for binding the polypeptide to an immunoglobulin. 1 1 . A polypeptide according to Claim 10 wherein said third domain is a tandem repeat synthetic IgG binding domain derived from domain β of Staphylococcal protein A. 1 2. A polypeptide according to Claim 9 wherein said third domain comprises an amino acid sequence that binds to a cell surface receptor. 1 3. A polypeptide according to Claim 1 2 wherein said third domain is insulin-like growth factor-1 (IGF- 1 ) . 14. A polypeptide according to any preceding claim comprising a botulinum toxin light chain or a fragment or a variant of a botulinum toxin light chain and a portion designated H N of a botulinum toxin heavy chain. 1 5. A polypeptide according to Claim 14 wherein one or both of (a) the toxin light chain or fragment or variant of toxin light chain and (b) the portion of the toxin heavy chain are of botulinum toxin type A. 1 6. A polypeptide according to Claim 1 5 wherein the botulinum toxin type A light chain variant has at residue 2 a glutamate, at residue 26 a lysine and at residue 27 a tyrosine. 1 7. A polypeptide according to Claim 14 wherein one or both of (a) the toxin light chain or fragment or variant of toxin light chain and (b) the portion of the toxin heavy chain are of botulinum toxin type B. 1 8. A polypeptide according to any of Claims 1 - 1 3 comprising a botulinum toxin light chain or a fragment or a variant of a botulinum toxin light chain and at least 100 N-terminal amino acids of a botulinum toxin heavy chain. 1 9. A polypeptide according to Claim 1 8 comprising a botulinum toxin type B light chain, or a fragment or variant thereof, and 107 N-terminal amino acids of a botulinum toxin type B heavy chain. 20. A polypeptide according to Claim 1 5 or 1 6 comprising at least 423 of the N- terminal amino acids of botulinum toxin type A heavy chain. 21 . A polypeptide according to Claim 20 comprising a botulinum toxin type A light chain and 423 N-terminal amino acids of a botulinum toxin type A heavy chain. 22. A polypeptide according to Claim 20 comprising a botulinum toxin type A light chain variant wherein residue 2 is a glutamate, residue 26 is a lysine and residue 27 is a tyrosine, and 423 N-terminal amino acids of a botulinum toxin type A heavy chain. 23. A polypeptide according to Claim 1 7 comprising at least 41 7 of the N- terminal amino acids of botulinum toxin type B heavy chain. 24. A polypeptide according to Claim 23 comprising a botulinum toxin type B light chain and 41 7 N-terminal amino acids of a botulinum toxin type B heavy chain. 25. A polypeptide according to any of Claims 1 4-24 lacking a portion designated H c of a botulinum toxin heavy chain. 26. A polypeptide comprising a botulinum toxin light chain and a fragment of a botulinum toxin heavy chain, said fragment being not capable of binding to cell surface receptors. 27. A polypeptide according to Claim 26 lacking an intact portion designated H c of a botulinum toxin heavy chain. 28. A polypeptide according to any preceding claim comprising a variant of a clostridial toxin and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin. 29. A polypeptide according to Claim 28 comprising a variant of a clostridial toxin light chain and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin light chain. 30. A polypeptide according to Claim 28 or 29 comprising a variant of a clostridial toxin heavy chain H N portion and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin heavy chain H N portion. 31 . A polypeptide according to Claim 28, 29 or 30 obtainable by modification of a DNA encoding the polypeptide so as to introduce one or more nucleotides coding for the cleavage site. 32. A fusion protein comprising a fusion of (a) a polypeptide according to any of Claims 1 -31 with (b) a second polypeptide being a polypeptide or oligopeptide adapted for binding to an affinity matrix so as to enable purification of the fusion protein using said matrix. 33. A fusion protein according to Claim 32 wherein said second polypeptide is adapted to bind to a chromatography column, such as an affinity matrix of glutathione Sepharose. 34. A fusion protein according to Claim 32 or 33 wherein a specific protease cleavage site is incorporated between the first and second polypeptides, said protease site enabling proteolytic separation of first and second polypeptides. 35. A composition comprising a derivative of a clostridial toxin, said derivative retaining at least 10% of the endopeptidase activity of the botulinum toxin, said derivative further being non-toxic in vivo due to its inability to bind to cell surface receptors, and wherein the composition is free of any component, such as toxin or a further toxin derivative, that is toxic in vivo. 36. A composition according to Claim 35 or a polypeptide according to any of Claims 1 -31 or a fusion protein according to Claim 32, 33 or 34 for use as a positive control in a toxin assay. 37. A composition according to Claim 35 or a polypeptide according to any of Claims 1 -31 or a fusion protein according to Claim 32, 33 or 34 for use as a vaccine against clostridial toxin. 38. A composition according to Claim 35 or a polypeptide according to any of Claims 1 -31 or a fusion protein according to Claim 32, 33 or 34 for in vivo use. 39. A pharmaceutical composition comprising a composition according to Claim 35, a polypeptide according to any of claims 1 -31 or a fusion protein according to Claim 32, 33 or 34, in combination with a pharmaceutically acceptable carrier. 40. A nucleic acid encoding a polypeptide or a fusion protein according to any of Claims 1 -34. 41 . A nucleic acid encoding a polypeptide or a fusion protein according to Claim 40 and comprising nucleotides encoding residues 1 -448 of a botulinum toxin type A light chain. 42. A nucleic acid according to Claim 40 or 41 comprising nucleotides encoding residues 1 -423 of a botulinum toxin type A heavy chain H N domain. 43. A nucleic acid encoding a polypeptide or a fusion protein according to Claim 40 and comprising nucleotides encoding residues 1 -470 of a botulinum toxin type B light chain. 44. A nucleic acid encoding a polypeptide or a fusion protein according to Claim 40 or 43 comprising nucleotides encoding residues 1 -41 7 of a botulinum toxin type B heavy chain H N domain. 45. A nucleic acid according to any of Claims 40-44 comprising nucleotides encoding a restriction endonuclease cleavage site not present in native clostridial toxin sequence. 46. A nucleotide according to Claim 45 obtainable by modification of a nucleotide encoding a polypeptide or fusion protein according to any of claims 1 -34 so as to introduce said cleavage site. 47. A DNA according to any of claims 40-46. 48. A DNA selected from SEQ ID No:s 1 , 8, 1 0, 1 2, 14, 1 6, 1 8, 23 and 24. 49. A method of manufacture of a polypeptide according to any of Claims 1 -31 comprising expressing in a host cell a nucleic acid according to any of Claims 40- 48 and recovering the polypeptide. 50. A method of manufacture of a polypeptide according to any of Claims 1 -31 comprising expressing in a host cell a nucleic acid encoding a fusion protein according to Claim 32, 33 or 34, purifying the fusion protein by eluting the fusion protein through an affinity matrix adapted to retain the fusion protein and eluting through said matrix a ligand adapted to displace the fusion protein, and recovering the fusion protein. 51 . A method of manufacture according to Claims 49 or 50 in which the nucleic acid is DNA. 52. A cell expressing a polypeptide or fusion protein according to any of Claims 1 -34.

Inventors: FOSTER KEITH ALAN, QUINN CONRAD PADRAIG, SHONE CLIFFORD CHARLES, FOSTER, KEITH, ALAN;, QUINN, CONRAD, PADRAIG;, SHONE, CLIFFORD, CHARLES;
Applicants: FOSTER KEITH ALAN, MICROBIOLOGICAL RES AUTHORITY, QUINN CONRAD PADRAIG, SHONE CLIFFORD CHARLES, SPEYWOOD LAB LTD, FOSTER, KEITH, ALAN;, MICROBIOLOGICAL RESEARCH AUTHORITY CAMR (CENTRE FO, QUINN, CONRAD, PADRAIG;, SHONE, CLIFFORD, CHARLES;, THE SPEYWOOD LABORATORY LIMITED
Application year: 1997
Main classification: C12N15
IPC codes: A61K38, A61K39, A61K47, A61K48, A61P31, C07K14, C07K19, C12N1, C12N5, C12N9, C12N15, C12P21, C12R1